Document:

EX-10.30

 Exhibit 10.30 

***Text Omitted and Filed Separately 

with the Securities and Exchange Commission 

Confidential Treatment Requested 

Under 17 C.F.R. Sections 200.80(b)(4) 

and 230.406 
 AGREEMENT

 AUGUST 2, 2016 

This Agreement (the “Agreement”) is effective as of the last date of signature found below (the
“Effective Date”) and is made by and between BioNano Genomics, Inc., a California corporation having a place of business at 9640 Towne Centre Drive, Ste. 100, San Diego, California 92121, (“BioNano”) and Berry
Genomics Co., Ltd., a Chinese corporation having a place of business at Building 9, Courtyard 6, East Jingshun Road, Chaoyang District, Beijing 100015, People’s Republic of China (“Berry”). BioNano and Berry may also
individually be referred to herein as a “Party” and collectively as the “Parties”. 
 WITNESSETH:

 WHEREAS, Berry desires to manufacture and commercialize in-vitro diagnostic
system using components supplied by BioNano in the Territory (as defined herein); 
 WHEREAS, Berry will purchase from
BioNano and BioNano will supply certain components for both the kits and instrument; 
 WHEREAS, Berry will take such
components and manufacture the finished kits and instruments at its sole cost; 
 WHEREAS, Berry will obtain all necessary
regulatory approvals in China to manufacture and sell the kits and instruments at its sole cost; 
 WHEREAS, BioNano will
provide certain training to enable Berry’s after-sales installation and support for the instrument. 
 NOW, THEREFORE,
for and in consideration of the premises and the mutual covenants contained herein, and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties hereto do hereby agree as follows: 

Article I. 
 Definitions

 The following capitalized terms shall have the respective meanings set forth below: 

“Affiliate” means, with respect to any Person, any other Person that, directly or indirectly, through one or more
intermediaries’ controls, is controlled by, or is under common control with, such Person. For purposes of this definition, “control” means the possession, direct or indirect, of the power to direct or cause the direction of the
management and policies of a Person, whether through ownership of voting securities or general partnership or managing member interests, by contract or otherwise. Without limiting the generality of the foregoing, a Person shall be deemed to control
any other Person in which it owns, directly or indirectly, a majority of the ownership interests. 
 “Authorized Third
Party” means a third party, other than an Affiliate of BioNano, that BioNano authorizes in writing for Berry to purchase BioNano Components from. 

  

					
	CONFIDENTIAL	  	1	  	

 “Berry Components” means those components of the IVD Kit(s) that are sourced by
or supplied by Berry, which are not supplied by BioNano or Authorized Third Party. For the avoidance of doubt, the BioNano Kit Components, including any associated documents, information, protocols, and methods of use, are not within the definition
of Berry Components. 
 “BioNano Intellectual Property Rights” means any and all Intellectual Property Rights owned by
BioNano or its Affiliates or licensed to BioNano or its Affiliates and sublicensable by BioNano to Berry. 
 “BioNano
Patents” means all BioNano patents and patent applications in the Territory to the extent pertaining to or covering aspects or features of the BioNano Components (or use thereof), IVD Kits and IVD Instrument (or use thereof) without regard
to (i.e., not particular to) any specific filed(s) of use or specific application(s). The BioNano Patents are set forth on Exhibit F. 

“BioNano Components” means those components that BioNano supplies to Berry under this Agreement for use in the IVD Kit(s) and
the IVD Instrument. The BioNano Components are set forth on Exhibit A. BioNano Components for the IVD Kit are referred to as “BioNano Kit Components” and BioNano Components for the IVD Instrument are referred to as “BioNano
Instrument Components.” 
 “Core IP” means any and all BioNano Intellectual Property Rights to the extent pertaining
to or covering aspects or features of the BioNano Components(or use thereof), IVD Kits and IVD Instrument (or use thereof) without regard to (i.e., not particular to) any specific field(s) of use or specific application(s). For clarity, Core IP
includes BioNano Patents, but excludes any trademark, service mark, trade dress, brand names, marks, or logos. 
 “CFDA”
means the China Food and Drug Administration (including the affiliated centers, such as the Center for Drug Evaluation, Center for Medical Device Evaluation, and the National Institutes for Food and Drug Control under it), any local Food and Drug
Administration or any successor governmental authority having substantially the same function. 
 “Clinical Partner” means
Berry’s collaboration partners, which Berry receives clinical samples from or provides clinical testing on site, including but not limited to the following: clinical laboratories, hospitals, clinics, etc. 

“Intellectual Property Right(s)” means all rights in patent, copyrights (including rights in computer software), know-how, trademark, service mark and trade dress rights and other industrial or intellectual property rights under the Laws of any jurisdiction, whether registered or not and including all applications or rights to
apply therefor and registrations thereto. 
 “Instrument Manufacturing Instructions” means a written document executed by
the authorized representatives of BioNano and Berry that details how the BioNano Instrument Components will be assembled into the finished IVD Instrument, including by way of example, shipping, storage, and handling requirements, as well as testing
to be conducted prior to shipment of IVD Kits to Berry’s customers. 
 “Instrument Specifications” means the
performance specifications for the IVD Instrument as set forth in Exhibit C. 

  

					
	CONFIDENTIAL	  	2	  	

 “IVD Certified Labs” means medical laboratories or medical institutions approved
by the National Health and Family Planning Commission of the PRC to undertake clinical use of genetic sequencing products or technologies under the applicable regulations. 

“IVD Instrument” means a complete diagnostic Berry-branded or Berry and BioNano co-
branded instrument comprised of the BioNano Instrument Components supplied to Berry by BioNano under this Agreement. 
 “IVD
System” means a complete system comprised of the IVD Instruments and the IVD Kits, including, for clarity, (i) algorithms, (ii) protocols, (iii) firmware, (iv) chips, (v) reagents, or (vi) other related items
therein. 
 “IVD Kit” means a complete diagnostic test for use with the IVD Instrument, which test comprises at least
(i) Berry Components that are test-specific elements supplied by Berry (e.g., primers, enzymes); (ii) BioNano Kit Components supplied to Berry by BioNano under this Agreement; and (iii) analysis/interpretation software developed by Berry
that will accept IVD Instrument standard output files and operate with the IVD Instrument. 
 “Kit Specifications” means
the performance specifications for the IVD Kit. 
 “Kit Manufacturing Instructions” means a written document executed by
authorized representatives of BioNano and Berry that details how BioNano Kit Components will be assembled into finished IVD Kits, including by way of example, [...***...]. 

“Law” means all statutes, statutory instruments, regulations, ordinances, or legislation to which a Party is subject; common
law and the law of equity as applicable to the Parties; binding court orders, judgments or decrees; industry code of practice, guidance, policy or standards enforceable by law; and applicable, directions, policies, guidance, rules or orders made or
given by a governmental or regulatory authority. 
 “[...***...]” means
[...***...]. 
 “Other IP” means any and all Intellectual Property Rights of third
parties to the extent pertaining to or covering aspects or features of the BioNano Components (or use thereof) or the IVD Instrument/Kit (or use thereof) with regard to any specific field(s) of use or specific application(s). 

“Patent Rights” means any and all patents, patent applications, provisional applications, certificates of invention,
applications for certificate of invention or priority patent filings, including any patents issuing on any such patent application or any certificate of invention issuing on any such application for certificate of invention, and including any
substitutions, extensions or supplementary protection certificates, patents of addition, reissues, reexaminations, extensions, restorations, confirmations, registrations, revalidations, revivals, revisions, renewals, divisions, continuations, continuation-in-parts or requests for continued examination of any of the foregoing. 

  
 ***Confidential
Treatment Requested 
  

					
	CONFIDENTIAL	  	3	  	

 “Person” means any individual or corporation, association, partnership, limited
liability company, joint venture, joint stock or other company, business trust, trust, organization, university, college, governmental authority or other entity of any kind. 

“Regulatory Approval” means all approvals, licenses and consents, clearances, and registrations from applicable governmental
authorities and healthcare institution authorities (including without limitation independent ethics committees) required in connection with the importation, clinical studies, registration, manufacture, distribution, promotion and advertising,
including Sale, of the IVD System, IVD Kit and IVD Instrument in the Territory in the Fields of Use. 
 “Sell”
“Sale” “Sold” means to sell, lease, loan, transfer, or otherwise dispose of. 
 “Service
Contract” means the maintenance and service support that Berry may purchase from BioNano for IVD Instruments and IVD Kits at its sole discretion upon the expiration of the [...***...] warranty. 

“Specifications” means BioNano’s written specifications for the BioNano Components in effect on the date the BioNano
Components are shipped from BioNano to Berry. 
 “Term” is defined in Section 9.01. 

“Territory” means the People’s Republic of China, excluding, for purposes of this Agreement only, the Hong Kong and
Macau Special Administrative Regions and Taiwan. 
 Article II. 

Responsibilities of the Parties 

2.01    Berry Responsibilities. Subject to the terms and conditions of this Agreement, Berry and Affiliate
of Berry, under their own names, at their sole cost and expense, shall: 
 (a)    manufacture and test
the IVD Instrument in accordance with the Instrument Manufacturing Instructions; 
 (b)    manufacture
and test the IVD Kits in accordance with the Kit Manufacturing Instructions; 
 (c)    market and Sell
IVD Instruments in the Territory that have been manufactured and tested in accordance with the Instrument Manufacturing Instructions in the Territory; 

(d)    market and Sell IVD Kits in the Territory that have been manufactured and tested in accordance with
the Kit Manufacturing Instructions in the Territory; 
 (e)    for the purpose of the above (a) –
(d), seek and obtain Regulatory Approvals for the IVD Kits and IVD Instrument and maintain such Regulatory Approvals thereafter during the Term; 

(f)    purchase the BioNano Components from BioNano as set forth in Exhibit A and terms and conditions of
this Agreement; 

  
 ***Confidential
Treatment Requested 
  

					
	CONFIDENTIAL	  	4	  	

 (g)    provide technical support for the IVD Kits and IVD
Instrument as set forth in Exhibit B; and 
 (h)    pay for BioNano’s
[...***...] costs incurred in providing IVD Instrument training to Berry personnel. 

2.02    BioNano Responsibilities. Subject to the terms and conditions of this Agreement, BioNano shall: 

(a)    provide the necessary support and documentation for the BioNano Components for each submission to a
Regulatory Authority; 
 (b)    manufacture and supply the BioNano Components to Berry that meet the
Instrument Specifications and Kit Specifications [...***...] in accordance with the terms and conditions of this Agreement; 

(c)    provide trainings to Berry so that Berry can perform IVD Instrument and IVD Kit manufacturing,
installation, service and support and effectively use BioNano Components; 
 (d)    provide, to the
extent permitted by all applicable Laws, installation, technical, warranty, and maintenance support for the IVD Kits and IVD Instrument, as applicable, as set forth in Exhibit B; 

(e)    assist Berry to manufacture, as applicable, the IVD Kits and IVD Instrument by using the BioNano
Components; 
 (f)    develop or co-develop with Berry the Kit
Component(s) and/or Instrument Component(s) to meet the Specifications for the Clinical Use; and 

(g)    provide the maintenance and service support if Berry purchase such service from BioNano upon the
expiration of the [...***...] warranty. 
 Article III. 

Regulatory Approval and Regulatory Documents 

3.01    Regulatory Approval. Berry is entitled to obtain the Regulatory Approvals on
its behalf under Berry’s name and brand collectively or respectively for the IVD System, IVD Instrument, and IVD Kit. Berry will act at its sole discretion in performing its relevant obligations for Regulatory Approvals. 

3.02    Regulatory Documents. Berry agrees that it will prepare any and all documents, materials, and
information necessary to seek, obtain, and maintain the Regulatory Approvals. BioNano agrees to provide all necessary documents, information and material timely and assist and/or participate in obtaining the necessary Regulatory Approvals, at
Berry’s cost and expense. 

  
 ***Confidential
Treatment Requested 
  

					
	CONFIDENTIAL	  	5	  	

 Article IV. 

Fields of Use; Sales and Marketing 

4.01    Fields of Use. Berry is entitled to develop and offer Berry-branded IVD System
for [...***...] in the following defined fields (“Clinical Use” or “Fields of Use”), with the potential to expand to other fields upon mutual agreement of both parties in the future. 

(a)    [...***...] in both prenatal and postnatal patients; 

(b)    [...***...]; 

(c)    [...***...] for In Vitro Fertility (IVF) centers and hospitals. 

4.02    Sale for Clinical Use. Subject to the terms and conditions of this Agreement,
including without limitation, the limited scope of rights conferred upon Berry under Section 7.01 and the Trademark License attached as Exhibit E, BioNano agrees that Berry may Sell IVD Kits and IVD Instruments for Clinical Use in
the Territory in the Fields of Use, [...***...]. The Parties agree that Berry is entitled to place instruments at Clinical Partner sites in the Territory at Berry’s sole cost. 

4.03    Sale for Research Use. BioNano agrees that Berry may Sell and distribute the IVD Kits
and IVD Instruments to IVD Certified Labs in the Territory for research use (“Research Use”), and use the IVD Kits and IVD Instruments for internal research (“Internal Use”). 

4.04    Distributors. In the event that Berry Sells through distributors, Berry agrees that it will only
Sell IVD Kits and IVD Instruments through distributors that are qualified and otherwise permitted by Law to market and Sell in-vitro diagnostic medical devices. 

4.05    Forward Information. BioNano and its distributors (if any) should forward the information to Berry
if it receives any inquiry regarding the purchase of IVD Kits and IVD Instruments from potential customers. 

4.06    Product Manuals and Marketing Collateral. Berry agrees [...***...] to
develop labeling, package inserts, user manuals/guides, and all marketing collateral, including websites (collectively “Collateral”), for the IVD Kits and IVD Instruments. 

4.07    [...***...]. [...***...]

  
 ***Confidential
Treatment Requested 
  

					
	CONFIDENTIAL	  	6	  	

 4.08    Instrument Specifications. The Instrument
Specifications are set forth in Exhibit C, which may be amended or updated by both Parties in writing. 

4.09    IVD Kit Specifications. Berry agrees that it will develop Kit Specifications similar to the
Instrument Specifications and provide BioNano with an English and Chinese version of the same upon request. 

4.10    Affiliate of Berry. Subject to the terms and conditions of this Agreement, BioNano agree that Berry
may use its Affiliate to manufacture and Sell the IVD Kit and IVD Instrument on behalf of Berry. 
 Article V. 

Branding and Trademarks 

5.01    Branding. The Parties agree that Berry will be entitled to manufacture the IVD Instruments and
IVD Kits under Berry’s brand names, marks, logo, trademarks and trade dress. Berry agrees that it will market and Sell the IVD Kits and IVD Instruments in compliance with the Branding Requirements set forth in Exhibit D. 

5.02    Berry Trademarks. BioNano recognizes the exclusive ownership by Berry of any proprietary Berry
marks, logo, trademarks or trade dress furnished by Berry (e.g. the name “Berry”) for use in connection with Berry’s commercialization of the IVD Instrument and IVD Kits. BioNano shall not, either during the Term, or at any time
thereafter, register, use or challenge or assist others to challenge the trademark, the Berry marks, logo and trade dress furnished by Berry or attempt to obtain any right in or to any such name, logo, trademarks or trade dress confusingly similar
for the marketing of the IVD Instrument and IVD Kits. 
 5.03    BioNano Trademarks. In the event the
Parties mutually agree to any co-branding, they shall enter into a Trademark License in the form attached as Exhibit E, which sets forth the terms and conditions under which Berry may use certain
trademarks of BioNano in connection with the marketing and Sale of the IVD Kits and IVD Instruments under this Agreement. 
 Article VI.

 Ordering, Delivery and Payment 

6.01    Component Pricing. The price for BioNano Components is set forth in Exhibit A. 

6.02    BioNano Components. Subject to the terms and conditions of this Agreement, Berry shall not purchase
products or materials from a third party (other than an Authorized Third Party) that would replace or be a substitute for the BioNano Components. For the avoidance of doubt, any BioNano Components purchased from an Authorized Third Party are subject
to the terms and conditions of this Agreement. 
 6.03    Ordering and Forecast. 

  

					
	CONFIDENTIAL	  	7	  	

 (a)    Ordering; Acceptance; Cancellation. Berry shall
order BioNano Components using written Purchase Orders submitted under and in accordance with this Agreement. Purchase Orders shall state, at a minimum, the BioNano part number, the BioNano provided quote number (or other reference provided by
BioNano), the quantity ordered, price, requested delivery date, and address for delivery, and shall reference this Agreement. All Purchase Orders shall be sent to the attention of BioNano Customer Solutions or to any other person or department
designated by BioNano in writing. Acceptance of a Purchase Order occurs when BioNano provides Berry a sales order confirmation (“Sales Order Confirmation”). BioNano shall provide Berry a Sales Order Confirmation within
[...***...] upon receipt of a Purchase Order. Purchase Orders submitted in accordance with this Agreement will not be unreasonably rejected by BioNano. BioNano shall provide justifications in writing for any rejection of
Purchase Orders. All Purchase Orders accepted by BioNano may not be modified without the prior written consent of Berry. 

(b)    Shipment. BioNano will ship BioNano Components to Berry. Certain BioNano Instrument
Components and Kit Components may be shipped directly from BioNano’s OEM manufacturers to Berry. 

(c)    Ship Date. BioNano will provide Berry with estimated ship dates within
[...***...] after a Sales Order Confirmation is issued. 
 (d)    Ship Date
Changes. The latest ship date allowed for any Component under a Purchase Order is the date that is [...***...] after a Sales Order Confirmation is issued. Subject to the terms and conditions of this Agreement, BioNano
will use reasonable efforts to accommodate Berry’s requests to bring forward the ship dates for BioNano Components on a Purchase Order accepted by BioNano. 

(e)    [...***...]. Berry shall, no later than the [...***...].

 (f)    Ship Schedule. Each Purchase Order for BioNano Components must include a ship schedule,
subject to BioNano’s confirmation, that details the quantity of and type of BioNano Components that Berry requires in each calendar month that is covered by the Purchase Order. 

6.04    Shipping; Title, Risk of Loss. Unless otherwise agreed upon in writing, all BioNano Components shall
be delivered ExWorks (Incoterms 2010) at BioNano’s shipping address and title and risk of loss shall transfer to Berry upon delivery at such address. For clarity, BioNano will be solely responsible for all formalities with the U.S. government
to ensure the delivery, including but not limited to handling all filings related to export and Customs clearance. 

6.05    Substantial Conformance. Shipments of BioNano Components from BioNano which do not conform to
the warranty set forth in Section 8.03, may be rejected by Berry within the time frames set forth in this Section 6.05. Berry will inspect all BioNano Components immediately upon receipt from BioNano. All BioNano Components shall be deemed
accepted by Berry [...***...] after receipt, unless rejected in accordance with this Section 6.05. To reject a BioNano Component, Berry shall give notice to BioNano not more than [...***...]
after receipt by Berry of a particular BioNano 

  
 ***Confidential
Treatment Requested 
  

					
	CONFIDENTIAL	  	8	  	

 
Component, stating the reasons for rejection. BioNano shall arrange for the pick-up of the rejected BioNano Component by BioNano’s
shipping/transportation company [...***...], which cost shall be [...***...] if the rejected BioNano Component is not a Qualifying Rejected Component. In the event the rejected BioNano Component
fails to conform to the warranty set forth in Section 8.03 (each being a “Qualifying Rejected Component”), BioNano shall, at BioNano’s election, either issue Berry a credit [...***...] for each
Qualifying Rejected Component or promptly replace the Qualifying Rejected Component with conforming BioNano Component. If the Parties disagree whether a particular BioNano Component is a Qualifying Rejected Component, the Parties shall submit a
sample of such BioNano Component to a mutually agreed independent laboratory for testing using the method set forth in the Specifications for such BioNano Component. The conclusion of such independent laboratory shall be binding upon the Parties,
and the Party against whom the independent laboratory rules shall bear the cost of such testing. 

6.06    Late Delivery. If BioNano fails to meet the delivery date for the products or material under a
Purchase Order, BioNano shall immediately notify Berry in writing and include the reasons therefore. If the failure is caused by BioNano (including BioNano’s suppliers, OEM and Authorized Third Party), BioNano shall take any and all
commercially reasonable actions necessary to fill Berry’s requirements as rapidly as possible, at BioNano’s expense. 

6.07    Invoice. All invoices shall be sent to Berry’s accounts payable department, or any other
address designated by Berry in writing. Invoices will be sent to Berry within [...***...] of shipment of the BioNano Components. 

6.08    Currency of Payments. All payments required under this Agreement shall be paid in United States
Dollars. 
 6.09    Payments. Berry agrees to pay for BioNano Components supplied and any amounts
payable arising under this Agreement in accordance with the terms and conditions of this Agreement. All payments are due within [...***...] of the date on the invoice. Without limiting any remedies available to BioNano,
any amounts not paid when due under this Agreement will accrue interest at the rate of [...***...]% per [...***...], or the maximum amount allowed by Law, if lower. 

6.10    Taxes. All prices and other amounts payable to BioNano hereunder are exclusive of and are payable
without withholding or deduction for taxes, GST, VAT, customs duties, tariffs, charges or otherwise as required by Law from time to time upon the Sale of the BioNano Components or provision of services, all of which will be added to the purchase
price or subsequently invoiced to Berry to gross up any payment in respect of which withholding or deduction is required to be made. 

6.11    Minimum Purchase. Berry agrees to place Purchase Orders for and take delivery of a quantity
of BioNano Instrument Components that is equal to five fully manufactured and ready to ship IVD Instruments within 12 months after the Effective Date per the following schedule: one unit of Irys V3 beta version ordered by September 30, 2016 and
delivered by October 15, 2016; one unit of Irys V3 beta version ordered by November 30, 2016 and delivered by December 15, 2016; one unit of Irys V3 (fully released version) delivered by March 31, 2017 and two units of Irys V3 (fully
released version) delivered by June 30, 2017. For the avoidance of doubt, the two units of Irys V2 that have been already purchased by Berry (order placed on June 23, 2016) are not included in the above schedule. Berry agrees to also place
Purchase Orders for and take delivery of a quantity of BioNano Instrument Components that is [...***...] 

  
 ***Confidential
Treatment Requested 
  

					
	CONFIDENTIAL	  	9	  	

 
[...***...] and the Instrument Specifications set forth in Exhibit C are met. Berry’s obligations under this Section 6.11 cease if this Agreement is
terminated pursuant to Section 9.02. 
 Article VII. 

Intellectual Property and Compliance 

7.01    Grant of License. As of the Effective Date, BioNano hereby grants to Berry and its
Affiliates, and Berry and its Affiliates hereby accepts, an irrevocable, exclusive, sublicensable, fully paid-up, royalty-free, license during the Term under the Core IP in the Territory in the Fields of Use
solely to seek and obtain CFDA registration, manufacture, market, distribute and have distributed, Sell and have Sold, offer for Sale and have offered for Sale IVD Kits and IVD Instruments For the avoidance of doubt, the license granted in this
Article 7.01 shall be at the exclusion of all others, including BioNano as the licensor. 
 7.02    IVD System
Improvements. 
 (a)    Subject to the terms and conditions of this Agreement, to the extent
permitted by PRC law, BioNano shall be the sole owner of all IVD System Improvements and Berry hereby assigns to BioNano any and all rights that Berry may have in the IVD System Improvements, provided that BioNano agrees to grant Berry an
irrevocable, nonexclusive, sublicensable, fully paid-up, royalty-free license during the Term in the Fields of Use in the Territory a) to use, reproduce, distribute, modify, and prepare derivative works of,
such IVD System Improvements solely to the extent necessary exploit the license granted Section 7.01, and b) to use, make, have made, offer for sale, sell, distribute and import products and services that incorporate, embody, or practice the
methods of, such IVD System Improvements, solely to the extent necessary exploit the license granted Section 7.01. Berry shall promptly disclose to BioNano any such IVD System Improvements that arise under this Agreement. Berry shall, at the
request of BioNano, assist BioNano to obtain, maintain and protect its ownership interests in the IVD System Improvements, the costs of which shall be afforded by BioNano. 

(b)    In the event that such IVD System Improvements are not permitted by the PRC laws to be transferred
to and owned by BioNano as provided in Section 7.02(a), then: (i) Berry unconditionally and irrevocably waives the enforcement of any rights in such IVD System Improvements and all claims and causes of action of any kind against BioNano
with respect to the rights; and (ii) to the extent Berry cannot (as a matter of law) make such waiver, Berry unconditionally grants to BioNano an exclusive, perpetual, irrevocable, worldwide, royalty free license, with the right to sublicense
through multiple levels of sublicensees, under any and all such rights: (x) to reproduce, create derivative works of, distribute, publicly perform, publicly display, digitally transmit, and otherwise use IVD System Improvements in any medium or
format, whether now known or hereafter discovered; (y) to use, make, have made, sell, offer to sell, import, and otherwise exploit any product or service based on, embodying, incorporating, or derived from IVD System Improvements; and
(z) to exercise any and all other present or future rights in IVD System Improvements. 
 (c)    As
used herein, “IVD System Improvements” shall mean all Patent Rights that are [...***...] and any improvements 

  
 ***Confidential
Treatment Requested 
  

					
	CONFIDENTIAL	  	10	  	

 thereto. For the avoidance of doubt, any improvement that is
non-related with [...***...] shall not be included in the IVD System Improvements. 

7.03    Other Improvements. Among the Parties, Berry shall be the sole and
exclusive owner of all rights, titles and interests in and to any and all Intellectual Property Rights, excluding IVD System Improvements, that are developed, directly or indirectly, by or on behalf of Berry, independently or with or through others
at any time, throughout the Term. 
 7.04    Other IP. Berry agrees that (i) it may
require Other IP to manufacture, distribute, market and Sell or otherwise exploit the IVD Kit and the IVD Instrument using BioNano Components in the Territory, and (ii) Berry is solely responsible to obtain the rights to any and all such Other
IP. BioNano will assist Berry in identifying and approaching the sources of such Other IP if BioNano is aware of such information or upon request from Berry.

7.05     No Implied Licenses. No right or license under any Intellectual Property Rights of a Party is
granted or shall be granted by implication to the other Party. All such rights or licenses are or shall be granted only as expressly provided in the terms of this Agreement, 

7.06    IP Enforcement. 

(a)    BioNano, on behalf of itself and its Affiliates (and their respective successors and assigns), shall
have the first right, but not obligation, to take any measures it deems appropriate to enforce BioNano Intellectual Property Rights. In the event of any third party infringes, misuses, misappropriates, or violates BioNano Intellectual Property
Rights in the Territory in the Fields of Use, Berry shall serve a written notice to BioNano. If BioNano elects not to take action with respect to enforcement actions to cease such infringement, misuse, misappropriation or violation, BioNano shall so
inform Berry within [...***...] upon receiving Berry’s notice, and Berry shall have the right, but not the obligation, to initiate actions to cease such infringement, misuse, misappropriation or violation. BioNano
agrees to provide reasonable assistance related to such enforcement actions as Berry may request at the cost and expenses of Berry. Berry may not offer or provide or sublicense to any third party in settlement or compromise of any such enforcement
action any intellectual property right belonging to or controlled by BioNano without the express written consent of BioNano. 

(b)    Among the Parties, enforcing Party shall bear the costs and expenses and retain all recovery and
income (including damages, licensing fees, royalties, settlement payments and other payments) received as a result of any enforcement action. 

7.07    IP Representations and Warranties by BioNano. BioNano hereby represents and warrants as of the
Effective Date to Berry that: 
 (a)    To its best knowledge, BioNano does not infringe any Intellectual
Property Rights of any third parties (especially third parties in the Territory); 
 (b)    BioNano has
not received any written claim alleging that any of BioNano’s activities relating to IVD Instrument and IVD Kits infringe, any Intellectual Property rights of any third parties; and 

  
 ***Confidential
Treatment Requested 
  

					
	CONFIDENTIAL	  	11	  	

 (c)    The deliverable materials and documents under
Section 7.08 will be provided on an “as is” basis. Any error or omission in such materials and documents – if any – shall be corrected by BioNano in the shortest possible time. 

7.08    BioNano Patents. Regarding the BioNano Patents, BioNano will either file national
entries based upon existing PCT applications designating the Territory, or file PCT applications and subsequent national entries designating the Territory, as applicable, either in its own name or together with Berry; provided, however, that if
BioNano determines to abandon or not to file any such entries or applications it shall provide reasonable prior notice of the same to Berry and Berry shall have the right to make or maintain such filings at Berry’s sole cost and expense by
providing reasonable notice thereof to BioNano. 
 7.09    BioNano will provide with Berry in a timely manner all
the information, materials, and documents regarding to, including without limitation, Intellectual Property Rights and Confidential Information in BioNano’s possession as of the date of this Agreement that is necessary for Berry’s licensed
activities under Section 7.01 within the Territory. Within [...***...] after the Effective Date, BioNano shall provide a checklist of such deliverable information, materials, and documents, which shall be attached
hereto as Exhibit G. 
 7.10    Compliance with Laws. 

(a)    Berry shall comply with applicable law pertaining to the manufacture, use, import, export,
transport, handling, storage, distribution, sales, and marketing, of the IVD Kits and IVD Instrument. 

(b)    In conformity with the applicable Chinese anti-bribery laws and regulations, the United States
Foreign Corrupt Practices Act (“FCPA”) and BioNano’s established corporate policies regarding foreign business practices, Berry and its directors, officers, employees and agents shall not directly or indirectly make an offer,
payment, promise to pay, or authorize payment, or offer a gift, promise to give, or authorize the giving of anything of value to any governments, government officials, political parties, political party officials (or relatives or associates of such
officials) or healthcare professionals for the purpose of influencing an act or decision of an official of any government or government instrumentality or a healthcare professional, including, without limitation, within the Territory or the United
States Government (including a decision not to act) or inducing such a person to use his influence to affect any governmental act or decision or act or decision of a healthcare institute in order to assist Berry, directly or indirectly, in
obtaining, retaining or directing any such business. 
 (c)    Berry will comply with all BioNano’s
reasonable requests in order to ensure compliance with the FCPA. Berry shall ensure that its employees and agents understand their obligations under the FCPA, and shall take such measures as may be necessary to ensure that its employees and agents
comply with its requirements. Berry’s efforts in this regard shall include, at a minimum, providing formal training to its employees and agents regarding the FCPA. Upon BioNano’s request, Berry shall provide to BioNano written confirmation
that it has conducted such training. 

  
 ***Confidential
Treatment Requested 
  

					
	CONFIDENTIAL	  	12	  	

 (d)    BioNano is committed to conducting its business in
accordance with BioNano’s Anti-Corruption Policy. Berry shall comply with BioNano’s Anti-Corruption Policy. Such obligations include, among others, prohibitions on receiving inappropriate gifts, payments or other compensation, and the
obligation to report relationships or transactions that could be expected to give rise to a conflict of interest. Berry acknowledges that BioNano has provided Berry with a copy of BioNano’s Anti-Corruption Policy and that BioNano may from time
to time provide Berry with revisions to the same. 
 Article VIII. 

Indemnification, Warranty and Limitation of Liability 

8.01    Infringement Indemnification. 

(a)    Indemnification by BioNano. Subject to these terms and conditions, 

(i)    BioNano shall defend, indemnify and hold harmless Berry and Affiliates of Berry, and its officers,
directors, representatives and employees, successors and assigns (each an “Berry Indemnitee”), against any and all claims, liabilities, damages, fines, penalties, causes of action, and losses of any and every kind
(“Claim”), including without limitation, claims relating to or arising out of personal injury or death, and claims arising out of infringement of a third party’s Intellectual Property Rights, in connection with any demands,
investigations, lawsuits and other legal actions of third parties to the extent a Claim results from, relates to, or arises out of (i) any breach of, or inaccuracy in, any representation or warranty made by BioNano in this Agreement,
(ii) any fault, negligence or intentional misconduct of BioNano, or its Affiliate, in performing or failing to perform under this Agreement, or (iii) any Claim of infringement of a third party’s Intellectual Property Rights (a
“BioNano Infringement Claim”); except in each case, to the extent such Claims result from the material breach of this Agreement by Berry or the negligence or willful misconduct of any Berry Indemnitee. 

(ii)    If the BioNano Components or any part thereof becomes, or in Berry’s opinion may become, the
subject of an BioNano Infringement Claim, upon Berry’s requirement, BioNano shall (A) procure for Berry the right to continue using the BioNano Components, (B) modify or replace the BioNano Components with a substantially equivalent non-infringing substitute, or (C) require the return of the BioNano Components then in Berry’s possession and terminate the rights, license, and any other permissions provided to Berry with respect the
BioNano Components and refund Berry the price paid by Berry for the returned BioNano Components at the time of such return. 

(b)    Indemnification by Berry. Berry shall defend, indemnify and hold harmless BioNano and
Affiliates of BioNano, and its officers, directors, representatives and employees, successors and assigns (each an “BioNano Indemnitee”), for any Claims in connection with any demands, investigations, lawsuits and other legal
actions of third parties to the extent arising from: (A) any breach of, or inaccuracy in, any representation or warranty made by Berry in this Agreement, and (B) any gross negligence or intentional misconduct of Berry, or its Affiliate, in
performing or failing to perform under this Agreement; except in each case, to the extent such Claims result from the material breach by BioNano of any covenant, representation, warranty or other agreement made by Berry in this Agreement, or the
negligence or willful misconduct of any BioNano Indemnitee. 

  

					
	CONFIDENTIAL	  	13	  	

 8.02    Indemnity Procedure. The Parties’ indemnification
obligations under this Article VIII are subject to the Party seeking indemnification (i) notifying the other, indemnifying Party promptly in writing of the claim, (ii) giving indemnifying Party exclusive control and authority over the
defense of such claim, (iii) not admitting infringement of any Intellectual Property Right without prior written consent of the indemnifying Party, (iv) not entering into any settlement or compromise of any such action without the
indemnifying Party’s prior written consent, and (v) providing all reasonable assistance to the indemnifying Party that the indemnifying Party requests and ensuring that its officers, directors, representatives and employees and other
indemnitees likewise provide assistance (provided that indemnifying Party reimburses the indemnified Party(ies) for its/their reasonable out-of-pocket expenses incurred
in providing such assistance). An indemnifying Party will not enter into or otherwise consent to an adverse judgment or order, or make any admission as to liability or fault that would adversely affect the indemnified party, or settle a dispute
without the prior written consent of the indemnified Party, which consent not to be unreasonably withheld, conditioned, or delayed. 

8.03    Product Warranty. 

(a)    BioNano Kit Components. To the extent permitted by PRC laws and regulations, BioNano
warrants that the BioNano Kit Components will conform to their Specifications until the later of (i) [...***...] from the date of shipment from BioNano, and (ii) any expiration date or the end of the shelf life pre-printed on such BioNano Kit Components by BioNano, but in no event later than [...***...] from the date of shipment. 

(b)    BioNano Instrument Components. To the extent permitted by PRC laws and regulations,
BioNano warrants that the BioNano Instrument Components will conform to their Instrument Specifications until [...***...] from the date of shipment from BioNano. Berry, at its sole discretion, may determine to purchase
Service Contract from BioNano upon expiration of such [...***...] warranty, and instruct BioNano relevant personnel to provide maintenance and service support to the customers of Berry. 

(c)    Limitations. To the extent permitted by PRC laws and regulations, the warranties in
Section 8.03(a) and 8.03(b) do not apply to the extent a non-conformance is due to (i) abuse, misuse, neglect, negligence, accident, improper storage, handling or use contrary to the Specifications
or Instrument Specifications, (ii) unauthorized alterations, (iii) Force Majeure events, or (iv) failure to manufacture the IVD Kit or IVD Instrument in accordance with the Kit Manufacturing Instructions and Instrument Manufacturing
Instructions, respectively. 
 (d)    Remedy. Berry’s exclusive remedy under the warranty in
Section 8.03(a) and 8.03(b) is that BioNano will, at BioNano’s option, replace or repair non-conforming BioNano Components that BioNano confirms is covered by this warranty. Replaced BioNano
Components come with a new warranty. 
 (e)    Procedure. In order to be eligible for replacement
under this warranty Berry must (i) promptly contact (orally or by written notice) BioNano’s support department to report the non-conformance within [...***...] after it
becomes aware of the non-conformance, (ii) cooperate with BioNano in confirming or diagnosing the non-conformance, and (iii) destroy or return the BioNano
Components, transportation charges assumed by BioNano following BioNano’s instructions. 

  
 ***Confidential
Treatment Requested 
  

					
	CONFIDENTIAL	  	14	  	

 (f)    Warranty Provided to Berry’s End-Customers. 
  

	 	1)	IVD Kit. To the extent permitted by PRC laws and regulations, Berry may determine the terms of the warranty it provides for the IVD Kit in its discretion; provided that, such warranty does not exceed the warranty
on the BioNano Kit Components provided by BioNano to Berry. 

  

	 	2)	IVD Instrument. To the extent permitted by PRC laws and regulations, Berry agrees that it will only convey the following warranty to end-customers of the IVD Instrument.

 “Warranty. Berry will only warrant that the IVD Instrument will conform to the Instrument Specifications for a
period of [...***...] beginning on the date the IVD Instrument is installed at the end-user customer’s site or [...***...] after the date the IVD
Instrument is delivered to the end-customer site, whichever occurs first. 
 Procedure for
Warranty Coverage. In order to be eligible for repair or replacement under this warranty, the end-customer must (i) promptly contact (orally or by written notice) the designated support contact to
report the non-conformance, (ii) cooperate in confirming or diagnosing the non-conformance, and (iii) return the IVD Instrument, transportation charges prepaid
following Berry’s instructions or, if agreed by Berry and end-user customer, grant Berry’s authorized repair personnel access to the IVD Instrument in order to confirm the non-conformance and make repairs. 
 Sole Remedy under Warranty. Berry will, at its option, repair
or replace non-conforming IVD Instrument that it confirms is covered by this warranty. IVD Instruments may be repaired or replaced with functionally equivalent, reconditioned, or new IVD Instruments or
components (if only a component of IVD Instrument is non-conforming). If the IVD Instrument is replaced in its entirety, the warranty period for the replacement is [...***...] from
the date of shipment or the remaining period on the original IVD Instrument warranty, whichever ends later. If only a component is being repaired or replaced, the warranty period for such component is [...***...] from the
date of shipment or the remaining period on the original IVD Instrument warranty, whichever ends later. The preceding states Berry’s sole remedy and Seller’s sole obligations under the warranty provided hereunder.” 

8.04    Berry Warranty. Berry warrants that it will perform the necessary manufacturing, marketing and tests
in compliance with the applicable PRC laws and regulations, and that the IVD Instruments and IVD Kits will be manufactured under appropriate design control and regulations for good manufacturing practices. 

8.05    Warranty Disclaimer. EXCEPT AS EXPRESSLY PROVIDED IN THIS AGREEMENT, NO WARRANTIES, EXPRESS OR
IMPLIED, ARE GIVEN BY EITHER PARTY, INCLUDING WITHOUT LIMITATION, ANY IMPLIED WARRANTY OF MERCHANTABILITY OR FITNESS FOR ANY PURPOSE. 

  
 ***Confidential
Treatment Requested 
  

					
	CONFIDENTIAL	  	15	  	

 8.06    Limitation on Liabilities. EXCEPT FOR DAMAGES RESULTING
FROM A BREACH OF A PARTY’S OBLIGATIONS UNDER ARTICLE 10, OR A PARTY’S INDEMNIFICATION OBLIGATIONS UNDER THIS ARTICLE 8, NEITHER PARTY WILL BE LIABLE WITH RESPECT TO ANY SUBJECT MATTER OF THIS AGREEMENT UNDER ANY CONTRACT, NEGLIGENCE,
STRICT LIABILITY, OR OTHER LEGAL OR EQUITABLE THEORY FOR ANY INCIDENTAL OR CONSEQUENTIAL DAMAGES, OR LOST PROFITS. 
 Article IX. 

Term and Termination 

9.01    Term. The term of this Agreement shall begin on the Effective Date and shall continue for
three (3) years (the “Term”), with option to renew for two (2) years by either Party. If either Party desires to continue this Agreement beyond the Term it shall notify in writing the other
Party of such desire at least 90 days before the end of the Term and the Parties will discuss such renewal. Notwithstanding the preceding two sentences, BioNano and Berry agree to in good faith negotiate the terms of a new supply agreement or
amendment to this Agreement in the event that this Agreement expires after the renewed Term. 
 9.02    Early
Termination. Without limiting any other rights of termination expressly provided in this Agreement or under Law, this Agreement may be terminated early as follows: 

(a)    Breach of Provision. If a Party materially breaches this Agreement and fails to cure such
breach within 30 days after receiving written notice of the breach from the other Party, or if a breach is not curable, then the non-breaching Party shall have the right to terminate this Agreement with
immediate effect by providing written notice of termination to the other Party. 
 (b)    Bankruptcy
and Insolvency. A Party may terminate this Agreement, effective immediately upon written notice, if the other Party becomes the subject of a voluntary or involuntary petition in bankruptcy, for winding up of that Party, or any proceeding
relating to insolvency, receivership, administrative receivership, administration liquidation or company voluntary arrangement or scheme of arrangement with its creditors that is not dismissed or set aside within 60 days. In the event of any
insolvency proceeding commenced by or against Berry, BioNano shall be entitled to cancel any Purchase Order then outstanding and not accept any further Purchase Order until bankruptcy or insolvency proceeding is resolved. In the event of any
insolvency proceeding commenced by or against BioNano, Berry shall be entitled to cancel any Purchase Order then outstanding. 

(c)    Termination for Failure to Purchase. BioNano shall have the right to terminate this
Agreement immediately upon written notice to Berry if Berry fails to achieve the purchase of the quantity of BioNano Instrument Components as set forth in Section 6.11, unless such failure is caused by the BioNano’s breach of its supply
obligations hereunder. 
 (d)    Termination for Infringement of Intellectual Property Rights in
China. Berry shall have the right to terminate this Agreement upon written notice to BioNano if a court of competent jurisdiction makes a final determination that in the course of its performance under this Agreement BioNano infringes the
Intellectual Property Rights of a third party in China. 

  

					
	CONFIDENTIAL	  	16	  	

 9.03    Effects of Termination on Inventory. In the event this
Agreement is terminated early pursuant to Section 9.02(c), and Berry has inventory of BioNano Components, finished IVD Kits, or IVD Instruments, BioNano and Berry will negotiate in good faith the terms of an exchange or credit program. In
addition, Berry shall have the right following expiration or termination of this Agreement, to manufacture in the Territory and Sell IVD Kits and IVD Instruments in accordance with the terms and conditions in the Agreement in order to dispose of
Berry’s inventory of BioNano Components, IVD Kits and IVD Instruments remaining un-Sold at the time of termination or expiration of this Agreement. 

9.04    Survival Obligations. All payment obligations, Article I, Article VIII, Article X, and
Article XI in their entirety, and Section 4.10, Sections 6.04, 6.09, 6.11, Sections 7.01, 7.02, 7.03, 7.04 and 7.05, 7.06, Sections 8.05, 8.06, the last sentence of Section 9.01, Sections 9.03 and 9.04, the entirety of Article XII, except
for Sections 12.03 and 12.09, shall survive the termination or expiration of this Agreement for any reason. Termination or expiration of this Agreement shall not relieve the Parties of any liability or obligation which accrued hereunder prior to the
effective date of such termination or expiration nor preclude either Party from pursuing all rights and remedies it may have hereunder or at law or in equity with respect to any breach of this Agreement, nor prejudice either Party’s right to
obtain performance of any obligation. 
 Article X. 

Protection of Confidential Information 

10.01    Confidentiality. The Parties acknowledge that a Party (the “Recipient Party”) may
have access to information (“Confidential Information”) of the other Party (the “Disclosing Party”) in connection with this Agreement. 

(a)    BioNano and Berry agree that in order for BioNano’s information to be protected as Confidential
Information, BioNano must disclose it with a confidential or other similar proprietary legend and in the case of orally or visually disclosed information, BioNano shall notify Berry of its confidential nature at the time of disclosure
[...***...] to Berry within [...***...] [...***...]. 

(b)    BioNano and Berry agree that all information of Berry and its Affiliates, in any form, including
without limitation, information in written, oral, or visual form, that BioNano has access to under or in connection with this Agreement is protected as Confidential Information even if it is not marked with a confidential or other similar
proprietary legend. BioNano acknowledges that access to Berry’s information may come from third parties, including without limitation, Authorized Third Parties. Accordingly, all such information is to be protected as Berry Confidential
Information under this Agreement. BioNano and Berry further agree that all information in any way related to the subject matter of this Agreement that was disclosed to BioNano by Berry or a Berry Affiliate or by BioNano to Berry on or after
March 12, 2016 is subject to the confidentiality provisions of this Agreement. 
 (c)    Berry and
BioNano agree that all information of BioNano and its Affiliates, in any form, including without limitation, information in written, oral, or visual form, that Berry has access to under or in connection with this Agreement is protected as
Confidential Information even if it is not marked with a confidential or other similar proprietary legend. Berry acknowledges that access to BioNano’s information may come from third parties, including 

  
 ***Confidential
Treatment Requested 
  

					
	CONFIDENTIAL	  	17	  	

 without limitation, Authorized Third parties. Accordingly, all such information is to be
protected as BioNano Confidential Information under this Agreement. 
 (d)    During the Term of this
Agreement and thereafter, the Recipient Party agrees that it shall hold the Disclosing Party’s Confidential Information in confidence using at least the degree of care that is used by the Recipient Party with respect to its own Confidential
Information, but no less than reasonable care. The Recipient Party shall disclose the Confidential Information of the Disclosing Party solely on a need to know basis to its employees, contractors, officers, directors, representatives, and those of
its Affiliates, under written confidentiality and restricted use terms or undertakings consistent with this Agreement. The Recipient Party shall not use the Disclosing Party’s Confidential Information for any purpose other than exercising its
rights and fulfilling its obligations under this Agreement. The Confidential Information shall at all times remain the property of the Disclosing Party. The Recipient Party shall, upon written request of the Disclosing Party, return to the
Disclosing Party or destroy the Confidential Information of the Disclosing Party. Notwithstanding the foregoing, the Recipient Party may maintain one copy of the Disclosing Party’s Confidential Information to be retained by the Recipient
Party’s Legal Department for archival purposes only. 

  

					
	CONFIDENTIAL	  	18	  	

 (e)    In the event the Parties have other obligations of
confidentiality in other agreements executed between the Parties or their Affiliates prior to the Effective Date, and there is a good-faith question as to whether the information is subject to the confidentiality provisions of this Agreement or
those of such other prior agreements, the Parties agree that such information shall be subject to the confidentiality provisions of this Agreement. 

10.02    Exceptions. Notwithstanding any provision contained in this Agreement to the contrary, neither
Party shall be required to maintain in confidence or be restricted in its use of any of the following: (a) information that, at the time of disclosure to the Recipient Party, is in the public domain through no breach of this Agreement or breach
of another obligation of confidentiality owed to the Disclosing Party or its Affiliates by the Receiving Party; (b) information that, after disclosure hereunder, becomes part of the public domain by publication or otherwise, except by breach of
this Agreement or breach of another obligation of confidentiality owed to the Disclosing Party or its Affiliate by the Receiving Party; (c) information that was in the Recipient Party’s or its Affiliate’s possession at the time of
disclosure hereunder by the Disclosing Party unless subject to an obligation of confidentiality or restricted use owed to the Disclosing Party or its Affiliate; (d) information that is independently developed by or for the Recipient Party or
its Affiliates without use of or reliance on Confidential Information of the Disclosing Party; or (e) information that the Recipient Party receives from a third party where such third party was under no obligation of confidentiality to the
Disclosing Party or its Affiliate with respect to such information. The occurrence of (a), (b), (c), (d) or (e) above shall not be deemed to grant either Party any license or other right, express or implied, to any portion of the information or
other proprietary rights of the other Party relating thereto. Notwithstanding the exceptions of this Section 10.02, any compilation of otherwise public information in a form not publicly known shall be considered Confidential Information. 

10.03    Disclosures Required by Law. Either party may disclose Confidential Information of the other as
required by court order, operation of law, or government regulation (including but not limited to all applicable laws and regulations governing the filing with CFDA, China Securities Regulatory Commission, and Securities & Futures
Commission of Hong Kong); provided that, the disclosing party promptly notifies the other party of the specifics of such requirement prior to the actual disclosure, or promptly thereafter if prior disclosure is impractical under the circumstances,
uses diligent and reasonable efforts to limit the scope of such disclosure or obtain confidential treatment of the Confidential Information if available, and allows the other party to participate in the process undertaken to protect the
confidentiality of the other party’s Confidential Information, including without limitation, cooperating with the other party in its efforts to permit the disclosing party to comply with the requirements of such order, law, or regulation in a
manner that discloses the least amount necessary, if any, of the Confidential Information of the other party. 

10.04    Injunctive Relief. Each Party acknowledges that any use or disclosure of the other Party’s
Confidential Information other than in accordance with this Agreement may cause irreparable damage to the other Party. Therefore, in the event of any such use or disclosure or threatened use or threatened disclosure of the Confidential Information
of either Party hereto, the non-breaching Party shall be entitled, in addition to all other rights and remedies available at Law, to seek injunctive relief against the breach or threatened breach of any
obligations under this Article X. 

  

					
	CONFIDENTIAL	  	19	  	

 10.05    Disclosure of Agreement. Except as expressly provided
otherwise in this Agreement, neither Party may disclose this Agreement, the terms and conditions of this Agreement, including any financial terms thereof, and the subject matter of this Agreement to any third party without the prior written consent
of the other Party, which consent shall not be unreasonably withheld. 
 Article XI. 

Notices 

11.01    Notices. All notices required or permitted under this Agreement shall be in writing, in English,
and shall be deemed received only when (a) delivered personally; (b) 5 days after having been sent by registered or certified mail, return receipt requested, postage prepaid (or 10 days for international mail); or (c) 1 day after deposit with a
commercial express courier specifying next day delivery or, for international courier packages, 2 days after deposit with a commercial express courier specifying 2-day delivery, with written verification of
receipt. All notices shall be sent to the following or any other address designated by a Party using the procedures set forth in Section 11.02: 
  

			
	If to BioNano:	  	If to Berry:
		
	 BioNano Genomics, Inc.
 9640 Towne Centre Drive,
Ste. 100
 San Diego, CA 92121
 Attn: Erik Holmlin
	  	 Beijing Berry Genomics Co., Ltd.
 Building 9,
Courtyard 6
 East Jingshun Road,
 Chaoyang District, Beijing
100015
 P. R. China
 Attention: Daixing Zhou

		
	 With a copy to:
  

BioNano Genomics, Inc.
 9640 Towne Centre Drive, Ste. 100

San Diego, CA 92121
 Attn: General Counsel
	  	

 11.02    Both Parties may give written notice of a change of address and, after
notice of such change has been received, any notice or request shall thereafter be given to such Party at such changed address. 
 Article
XII. 
 Miscellaneous 

12.01    Publicity; Use of Names or Trademarks. Except as expressly authorized otherwise in this Agreement,
each Party shall obtain the prior written consent of the other Party on all press releases or other public announcements relating to this Agreement, including its existence or its terms, provided that a Party is not required to obtain prior written
consent of the other Party for press releases or public disclosures that repeat information that has been previously publicly disclosed. Berry and BioNano intend to announce their supply relationship in a press release and each agrees it will
undertake good faith efforts to reach mutual agreement on the text for release within [...***...] after the Effective Date. Except as 

  
 ***Confidential
Treatment Requested 
  

					
	CONFIDENTIAL	  	20	  	

 
expressly authorized otherwise in this Agreement, neither Party shall use the name or trademarks of the other Party without the express prior written consent of the other Party. 

12.02    Assignment; Performance by Affiliates. 

(a)    Berry shall not assign or transfer this Agreement or any rights or obligations to any third party,
without the prior written consent of the BioNano. Any assignment or transfer of this Agreement made in contravention of the terms hereof shall be null and void. Subject to the foregoing, this Agreement shall be binding on and inure to the benefit of
the Parties’ respective successors and permitted assigns. 
 (b)    Each Party recognizes that the
other Party may perform some or all of its obligations under this Agreement through Affiliates to the extent permitted under this Agreement; provided, however, that such other Party shall remain responsible for the performance by its
Affiliates as if such obligations were performed by such other Party. 
 12.03    Legal Compliance.
Nothing in this Agreement is intended, or should be interpreted, to prevent either Party from complying with, or to require a Party to violate, any and all applicable Laws. Should either Party reasonably conclude that any portion of this Agreement
is or may be in violation of a change in a Law made after the Effective Date, or if any such change or proposed change would materially increase the cost of any Party’s performance hereunder, the Parties agree to negotiate in good faith written
modifications to this Agreement as may be necessary to establish compliance with such changes and/or to reflect applicable changes in compensation necessitated by such changes, with any mutually agreed upon modifications added to this Agreement by
written amendment in accordance with Section 12.07 of this Agreement. 
 12.04    Governing Law;
Jurisdiction. This Agreement and any dispute or claim arising out of or in connection with it or its subject matter or formation shall be governed and construed in accordance with the laws of the State of Delaware; provided the Parties
shall abide by all applicable mandatory laws and regulations of the People’s Republic of China. All disputes, controversy, difference or claim arising out of or in connection with this Agreement, including without limitation, any question
regarding its existence, validity, interpretation, performance, breach or termination thereof or any dispute regarding non-contractual obligations arising out of or relating to it, shall be referred to and
finally resolved by arbitration administered by the American Arbitration Association (the “AAA”). The arbitration shall take place in accordance with the AAA rules then in effect. The tribunal shall consist of three arbitrators,
each of BioNano and Berry shall appoint one arbitrator, and the third arbitrator shall be appointed in accordance with the AAA rules and shall be the chairman, and shall not be a national of either Party, unless the Parties agree otherwise in
writing. Each arbitrator shall have no less than 10 years of experience handling disputes similar to the dispute to be arbitrated hereunder. The language of the arbitration shall be English. The arbitration shall be held in AAA’s office in the
State of Delaware. Any award made by the arbitral tribunal shall be final and binding on the Parties and each Party hereby waives to the fullest extent permitted by Law and right it may otherwise have under the laws of any jurisdiction to any form
of appeal. 

  

					
	CONFIDENTIAL	  	21	  	

 12.05    Severability. The terms and conditions stated herein
are declared to be severable. If any paragraph, provision, or clause in this Agreement shall be found or be held to be invalid or unenforceable in any jurisdiction in which this Agreement is being performed, the remainder of this Agreement shall be
valid and enforceable and the Parties shall use good faith efforts to negotiate a substitute, valid and enforceable provision which most nearly effects the Parties’ intent in entering into this Agreement. 

12.06    No Waiver; Rights and Remedies. The failure or delay of either Party to exercise any right
or remedy provided herein or to require any performance of any term of this Agreement shall not be construed as a waiver, and no single or partial exercise of any right or remedy provided herein, or the waiver by either Party of any breach of this
Agreement shall not prevent a subsequent exercise or enforcement of, or be deemed a waiver of any subsequent breach of, the same or any other term of this Agreement. Except as expressly provided in this Agreement, the rights and remedies of each
Party under this Agreement are cumulative and not exclusive of any rights or remedies provided by Law. 

12.07    Entire Agreement; Amendment; Waiver. This Agreement represents the entire agreement between the
Parties regarding the subject matter hereof and supersedes all prior discussions, communications, agreements, and understandings of any kind and nature between the Parties. The Parties acknowledge and agree that by entering into this Agreement, they
do not rely on any statement, representation, assurance or warranty of any person or entity other than as expressly set out in the Agreement. Each Party agrees that it shall have no right or remedy (other than for breach of contract) in respect of
any statement, representation, assurance or warranty (whether made negligently or innocently) other than as expressly set out in this Agreement. Nothing in this Section 12.07 shall exclude or limit liability for fraud. No amendment to this
Agreement will be effective unless in writing and signed by both Parties. No waiver of any right, condition, or breach of this Agreement will be effective unless in writing and signed by the Party who has the right to waive the right, condition or
breach and delivered to the other Party. 
 12.08    Counterparts. This Agreement may be executed in any
number of counterparts, each of which will be deemed an original, but all of which together will constitute but one and the same instrument. This Agreement will become effective when duly executed by each Party hereto. 

12.09    Cooperation. BioNano and Berry agree to execute any instruments reasonably believed by the
other Party to be necessary to implement the provisions of this Agreement. 
 12.10    Costs. Each
Party shall bear its own costs and expenses incurred in connection with the negotiation and execution of this Agreement. 

12.11    Force Majeure. Neither Party shall be in breach of this Agreement nor liable for any failure
to perform or delay in the performance of this Agreement attributable in whole or in part to any cause beyond its reasonable control, including but not limited to acts of God, fire, flood, tornado, earthquake, hurricane, lightning, any action taken
by government or a regulatory authority, actual or threatened acts of war, terrorism, civil disturbance or insurrection, sabotage, labor shortages or disputes, , transportation difficulties, interruption or failure of any utility service, raw
materials or equipment, or the other Party’s fault or negligence (each an event of “Force Majeure”). In the event of any such delay, the delivery date for performance shall be deferred for a period equal to the
time lost by reason of the delay. 
 12.12    Headings and Certain Rules of Construction. Sections, titles
and headings in this Agreement are for convenience only and are not intended to affect the meaning or interpretation hereof. 

  

					
	CONFIDENTIAL	  	22	  	

 This Agreement has been negotiated in the English language and only the English language version shall control.
Any translation of this Agreement into a non-English language is for convenience only. Whenever required by the context, the singular term shall include the plural, the plural term shall include the singular,
and the gender of any pronoun shall include all genders. As used in this Agreement except as the context may otherwise require, the words “include”, “includes”, “including”, and “such as” are deemed to be
followed by “without limitation”, whether or not they are in fact followed by such words or words of like import, and “will” and “shall” are used synonymously. The terms “hereof,” “herein,”
“hereby,” and derivative or similar to refer to this entire Agreement. Except as expressly stated, any reference to “days” shall be to calendar days, and “business day” shall mean all days other than Saturdays, Sundays
or a national or local holiday recognized in the United States and the People’s Republic of China, and any reference to “calendar month” shall be to the month and not a 30 day period, and any reference to “calendar quarter”
shall mean the first 3 calendar months of the year, the 4-6th calendar months of the year, the 7-9th calendar months of the year, and the last 3 calendar months of the
year. Whenever the last day for the exercise of any privilege or the discharge of any duty hereunder shall fall on, or any notice is deemed to be given on a Saturday, Sunday, or national holiday, the Party having such privilege or duty shall have
until 5:00 pm PST on the next succeeding business day to exercise such privilege or to discharge such duty or the Party giving notice shall be deemed to have given notice on the next succeeding business day. It is further agreed that no usage of
trade or other regular practice between the Parties hereto shall be used to interpret or alter the terms and conditions of this Agreement. Ambiguities, if any, in this Agreement shall not be construed against any particular Party, irrespective of
which Party may be deemed to have authored the ambiguous provision. 
 [signature page follows] 

  

					
	CONFIDENTIAL	  	23	  	

 IN WITNESS WHEREOF, effective as of the Effective Date, each of the Parties have executed this
Agreement in duplicate originals by their duly authorized officers or representatives. 
  

									
	BIONANO GENOMICS, INC.	 		 	BERRY GENOMICS CO., LTD.
					
	By:	 	 /s/ Erik Holmlin, Ph.D.
	 		 	By:	 	 /s/ Daixing Zhou

	Name:	 	Erik Holmlin, Ph.D.	 		 	Name:	 	Daixing Zhou
	Title:	 	President and Chief Executive Officer	 		 	Title:	 	CEO
					
	Date:	 	03 August 2016	 		 	Date:	 	8/3/2016

  

					
	CONFIDENTIAL	  	[Signature Page to IVD Agreement]	  	

 EXHIBIT A 

BIONANO COMPONENTS, SERVICE CONTRACTS, AND IQ/OQ PRICING 

BioNano Kit Components 
  

									
	 	  	 Product
	  	 Retail Price (or

Expected Retail

Price)
	  	 [...***...]
	  	 Transfer Price

	 Kits
	  		  		  		  	
		  	[...***...]	  	[...***...]	  	[...***...]	  	[...***...]
		  	[...***...]	  	[...***...]	  	[...***...]	  	[...***...]
					
	 Hardware
	  		  		  		  	
		  	[...***...]	  	[...***...]	  	[...***...]	  	[...***...]
		  	[...***...]	  	[...***...]	  	[...***...]	  	[...***...]
		  	[...***...]	  	[...***...]	  	[...***...]	  	[...***...]
					
	 Service Contracts
	  		  		  		  	
		  	[...***...]	  	[...***...]	  	[...***...]	  	[...***...]

 BioNano Instrument Components 
  

							
	 Item
	  	 Description
	  	 Part Number
	  	 U.S. List Price (USD)*

	 1
	  	[...***...]	  	[...***...]	  	[...***...]
	 2
	  	[...***...]	  	[...***...]	  	[...***...]
	 3
	  	[...***...]	  	[...***...]	  	[...***...]

  

	*	price reflects U.S. list price as of the Effective Date. List price may be subject to change upon mutual written agreement. 

  
 ***Confidential
Treatment Requested 
 CONFIDENTIAL 

 Service Contracts 
  

					
	 Part Number
	  	 Description
	  	 US List Price

	 [ ...***...]
	  	[ ...***...]	  	[... ***...] $
	 [... ***...]
	  	[... ***...]	  	[... ***...] $
	 [... ***...]
	  	[... ***...]	  	[... ***...] $
	 [... ***...]
	  	[... ***...]	  	[... ***...] $

  

	*	price reflects U.S. list price as of the Effective Date. List price is subject to change upon mutual written agreement. 

  
 ***Confidential
Treatment Requested 
 CONFIDENTIAL 

 EXHIBIT B 

SUPPORT 
  

	1.	Berry Obligations 

  

	 	a.	Technical Support 

 1st line support for IVD Kits and IVD Instruments (including
responding to customer questions and comments, and maintaining appropriate customer records for regulatory compliance) 
 Conduct validation
of IVD Kit in its labs and manufacturing site 
 Conduct validation for the quality of the results delivered to patients, using protocols
and methods of its choosing 
 Protocol training post instrument installation 

All support for issues specific to the protocols 
  

	2.	BioNano Obligations 

  

	 	a.	Installation 

 Conducts hardware installation and validation of IVD Instruments at Berry
facilities and its affiliates. 
  

	 	b.	Installation and support training 

 Train Berry’s support team to install, validate
and support IVD Instruments and BioNano Kit components. 
  

	 	c.	2nd line support for IVD Kits 

 Provide secondary support to Berry if they are unable to
resolve a problem with the IVD Kits. 
  

	 	d.	Warranty and Service Contract Support 

 Terms and conditions of service and support
during the warranty period or Service Contracts shall be further determined by Parties by mutual agreement. 

  

					
	CONFIDENTIAL	  		  	

 EXHIBIT C 

INSTRUMENT SPECIFICATIONS 

Specifications as contingency for the Irys V3 Beta systems purchased from Q3 16 to Q4 16: 

 

	1)	Throughput: [...***...] 

  

	2)	Detection sensitivity: [...***...] 

 Specifications as contingency for the Irys
V3 systems purchased from Q1 17 to Q2 17: 
  

	1)	Detection sensitivity: [...***...] 

  

	2)	Throughput: [...***...] 

  

	3)	Running chip cost: [...***...] 

  

	4)	Running time: [...***...] 

 Specifications as contingency for the Irys V3 systems
purchased beginning in Year 2 (which begins in Q3 17): 
  

	1)	Detection sensitivity: [...***...] 

  

	2)	Throughput: [...***...] 

  

	3)	Running chip cost: [...***...] 

  

	4)	Running time: [...***...] 

  
 ***Confidential
Treatment Requested 
 CONFIDENTIAL 

 EXHIBIT D 

BRANDING REQUIREMENTS 
 The following
constitutes the general initial Branding Requirements for the IVD Instrument and IVD Kits. 
  

			
	Branding of IVD Instrument	  	 •   Berry’s sole discretion to
brand as Berry Instrument or co-brand as a BioNano | Berry instrument.
  

•   Product name label will be supplied by BioNano. It will be placed on the instrument in the
upper left hand corner similar to standard product name placement on other BioNano instruments, if co-branding.
  

•   If co-branding, the BioNano logo will be supplied by BioNano and must be featured on the
lower right hand side of the front of the instrument. In addition the Berry logo will be placed next to the BioNano logo so that it is clear that the instrument is a co-branded product. Detailed
guidelines for placement and sizing of logos will be provided by Berry.
  

	Branding of IVD Kits	  	 •   Berry’s sole discretion to
brand as Berry IVD Kit or co-brand as a BioNano | Berry IVD Kit.

		
	Marketing of IVD Instrument and IVD Kit	  	 •   All materials referencing
BioNano brands must include appropriate trademark acknowledgements.

  
 CONFIDENTIAL 

 EXHIBIT E 

TRADEMARK LICENSE 
 This
Trademark License is incorporated into and made a part of that certain Agreement entered into by and between BioNano, Inc., a California corporation having a place of business at 9640 Towne Centre Drive, Ste. 100, San Diego, California 92121
(defined in the Agreement as “BioNano”) and Berry Genomics Co., Ltd., a Chinese corporation having a place of business at Building 9, Courtyard 6, East Jingshun Road, Chaoyang District, Beijing 100015, People’s Republic of
China (defined in the Agreement as “Berry”). 
 WHEREAS, BioNano is the owner of the [TBD] trademark (Application
#                     in the Trademark Office of the People’s Republic of China) including all registrations or applications therefore (the
“Mark”): 
 WHEREAS, pursuant to the Agreement, BioNano is granting certain rights to Berry to market and Sell IVD Kits and
IVD Instruments; and 
 WHEREAS, the Parties desire to incorporate this Trademark License into the Agreement, in order to grant Berry
certain rights to use the Mark in connection with the marketing and Sale of the IVD Kits and IVD Instruments. Capitalized terms used but not defined in this Trademark License will have the definition given to them in the Agreement. Notwithstanding
the inclusion of trademarks in the defined term “Intellectual Property Rights”, this Trademark License exclusively contains all rights granted to Berry under BioNano and its Affiliate(s) trademarks and service marks; 

NOW, THEREFORE, for and in consideration of the premises and the mutual covenants contained herein, and other good and valuable consideration,
the receipt and sufficiency of which are hereby acknowledged, the Parties hereto do hereby agree as follows: 

1.    License Grant. Subject to, and contingent upon Berry’s and the Authorized Affiliates (as defined below)
continued compliance with, all terms and conditions of the Agreement (specifically including the Branding Requirements set forth in Exhibit D) BioNano hereby grants to Berry and the Authorized Affiliates, and Berry hereby accepts, on
behalf of itself and such Authorized Affiliates, a royalty-free, non-exclusive, transferable, sublicensable, irrevocable, license to use the Mark during the Term solely to market, distribute and have
distributed, Sell and have Sold, offer for Sale and have offered for Sale, the IVD Kits and IVD Instruments in the Territory in the manner set forth in Section 2.01 of the Agreement, and to develop and distribute Collateral bearing the Mark in
furtherance of such activities in the manner set forth in Sections 4.01, 4.02 and 4.03 of the Agreement. As used herein, “Authorized Affiliate” means a Berry Affiliate expressly authorized under the Agreement to market and/or Sell
the IVD Kit and/or IVD Instrument in the Territory. 
 2.    Use of the Mark. 

2.01    Branding Requirements and Usage Guidelines. Berry and each Authorized Affiliate shall use the Mark in
conformity with the Branding Requirements set forth in Exhibit D to the Agreement, as such Branding Requirements may be updated upon BioNano and Berry’s mutual agreement from time to time, and any additional trademark usage guidelines as may be
determined upon BioNano and Berry’s mutual agreement from time to time. 

  
 CONFIDENTIAL 

 2.02    Marking. Berry and each Authorized Affiliate shall clearly
mark all IVD Kits and IVD Instruments with Berry’s name and address (and/or the name and address of the Authorized Affiliate(s), if appropriate) in compliance with Article 43 of the China Trademark Law. Berry and each Authorized Affiliate shall
include the following notice on all Collateral bearing the Mark, in the language predominantly used in such Collateral: 
 [TBD] is a
trademark of BioNano, Inc. and/or its affiliate in the People’s Republic of China used under license. 

3.    Ownership of the Marks. 

3.01    Ownership. Berry, on behalf of itself and each Authorized Affiliate, acknowledges and agrees that:
(i) BioNano is the owner of all right, title, and interest in and to the Mark; (ii) neither Berry nor any Authorized Affiliate has right or interest in the Mark other than those rights expressly granted in this Trademark License;
(iii) neither Berry nor any Authorized Affiliate has any right or interest in any other trademark or service mark of BioNano or its Affiliate. 

4.    Registration and Enforcement. 

4.01    Registration. BioNano shall use commercially reasonable efforts to seek, obtain and, during the Term,
maintain in its own name and at its own expense, registration of the Mark within the Territory. In the event that BioNano decides to abandon any of the Mark within the Territory, BioNano will inform Berry and Berry shall have the first right to
obtain the ownership of such Mark without costs. 
 4.02    Enforcement. BioNano has the right, but not the
obligation, to take action against any third party infringement of the Mark. In the event that Berry or any Authorized Affiliate learns of any potential infringement of the Mark by any third party, Berry shall promptly notify BioNano of the facts
concerning such potential infringement. If BioNano elects not to take action with respect to enforcement actions to cease such infringement, BioNano shall so inform Berry within [...***...] upon receiving Berry’s
notice, and Berry shall have the right, but not the obligation, to initiate actions to cease any such infringement in the Territory in the Fields of Use. Among the Parties, enforcing Party shall retain all recovery and income (including damages,
licensing fees, royalties, settlement payments and other payments) received as a result of any enforcement action. 

5.    Miscellaneous. 

5.01     Term and Termination. The term of this Trademark License shall commence on the Effective Date and shall
continue until the termination or expiration of the Agreement. Upon termination of this Trademark License, all rights and obligations hereunder shall automatically terminate. The termination of this Trademark License will not affect the validity of
the Agreement. 
 5.02    Governing Law. This Agreement and any dispute or claim arising out of or in connection
with it or its subject matter or formation shall be governed and construed in accordance with the laws of the State of Delaware; provided the Parties shall abide by all applicable mandatory laws and regulations of the People’s Republic of
China. All disputes, controversy, difference or claim arising out of or in connection with this Trademark License shall be resolved as set forth in Section 12.04 of the Agreement. 

  
 ***Confidential
Treatment Requested 
 CONFIDENTIAL 

 5.03    Assignment. Berry shall not assign or transfer this Agreement
or any rights or obligations under this Agreement, without the prior written consent of the BioNano. Any assignment or transfer of this Trademark License made in contravention of the terms hereof shall be null and void. Subject to the foregoing,
this Trademark License shall be binding on and inure to the benefit of the Parties’ respective successors and permitted assigns. 

5.04    Amendment and Waiver. No provision of this Trademark License may be amended or waived except by a writing
signed by both Parties. 
 IN WITNESS WHEREOF, effective as of the Effective Date, each of the Parties have executed this Agreement in
duplicate originals by their duly authorized officers or representatives. 
  

									
	BIONANO GENOMICS, INC.	 		 	BERRY GENOMICS CO., LTD.
					
	By:	 	  
	 		 	By:	 	 /s/ Daixing Zhou

	Name:	 	Erik Holmlin, Ph.D.	 		 	Name:	 	Daixing Zhou
	Title:	 	President and Chief Executive Officer	 		 	Title:	 	CEO
					
	Date:	 	  
	 		 	Date:	 	8/3/2016

  

					
	CONFIDENTIAL	  		  	

 EXHIBIT F 

BIONANO PATENTS 
  

											
	 Country
	  	 Applicant Title and

Number
	  	 Application

Date
	  	 Grant Number
	  	Grant Date	 
		  	[...***...]	  		  		  			
	[...***...]	  	[...***...]	  		  		  			
		  	[...***...]	  		  		  			
	[...***...]	  	[...***...]	  		  	[...***...]	  			
	[...***...]	  	[...***...]	  		  		  			
		  	[...***...]	  		  		  			
	[...***...]	  	[...***...]	  		  		  			
		  	[...***...]	  		  		  			
	[...***...]	  	[...***...]	  		  	[...***...]	  			
	[...***...]	  	[...***...]	  		  		  			
		  	[...***...]	  		  		  			
	[...***...]	  	[...***...]	  		  	[...***...]	  			
	[...***...]	  	[...***...]	  		  		  			
		  	[...***...]	  		  		  			
	[...***...]	  	[...***...]	  		  	[...***...]	  			
		  	[...***...]	  		  		  			
	[...***...]	  	[...***...]	  		  		  			
		  	[...***...]	  		  		  			
	[...***...]	  	[...***...]	  		  		  			
		  	[...***...]	  		  		  			
	[...***...]	  	[...***...]	  		  		  			
		  	[...***...]	  		  		  			
	[...***...]	  	[...***...]	  		  		  			
		  	[...***...]	  		  		  			
	[...***...]	  	[...***...]	  	[...***...]	  		  			
		  	[...***...]	  		  		  			
	[...***...]	  	[...***...]	  	[...***...]	  		  			
	[...***...]	  	[...***...]	  		  		  			
		  	[...***...]	  		  		  			
	[...***...]	  	[...***...]	  	[...***...]	  		  			
		  	[...***...]	  		  		  			
	[...***...]	  	[...***...]	  	[...***...]	  		  			
	[...***...]	  	[...***...]	  		  		  			

  

	*	PROVISIONAL US PATENT APPLICATIONS (Owner: BioNano) 

 Several unpublished patent applications disclosing new
technologies are in preparation for filing as provisional patent application 

  
 ***Confidential
Treatment Requested 
 CONFIDENTIAL 

	**	Patent License Agreement: 

 I. Licensor: Princeton University 

1. Scope License Rights: 
 a. Patent rights: 

• Princeton Patent Portfolio 
 [...***...] 

 

	•	 	[...***...] 

 [...***...] 
  

	•	 	[...***...] 

 b. [...***...] 

c. Princeton retains rights for non-commercial research and educational purposes. 

2. Scope: Exclusive 
 3. Territory: Worldwide 

4. Sublicense Rights: Yes 
 5. Covenant Not to Sue: One Princeton
designee: Nanonex Corporation 
 6. Technology improvements made by BioNano Genomics: Ownership retained by BioNano Genomics 

7. Patent prosecution and enforcement paid by Licensee. 
 8. Term:
Later of a) Last sale of Licensed Product or Service or b) the expiration of Princeton Patent Rights. 

  
 ***Confidential
Treatment Requested 
 CONFIDENTIAL 

 EXHIBIT G 

CHECKLIST OF DELIVERABLES 

[To be inserted] 

  
 CONFIDENTIALEX-10.31

 Exhibit 10.31 

***Text Omitted and Filed Separately 

with the Securities and Exchange Commission 

Confidential Treatment Requested 

Under 17 C.F.R. Sections 200.80(b)(4) 

and 230.406 
 PATENT
SUBLICENSE AGREEMENT 
 This Patent License Agreement (the “Agreement”), dated December 27, 2013 (the
“Effective Date”), is hereby entered into by and between Industry 3200, Inc., a Delaware Corporation with a principal office located at 1155 Camino Del Mar #118, Del Mar, CA 92014 (“Sublicensor”), and BioNano Genomics, Inc., a
Delaware Corporation, having a principal place of business at 9640 Towne Centre Drive, Suite 100 (“Sublicensee) 

WHEREAS Sublicensor holds a patent license (the Master License Agreement) from the [...***...]
(“[...***...]”) to intellectual property identified as the [...***...] portfolio; and 
 WHEREAS
Sublicensor desires to grant and Sublicensee desires to receive a sublicense under certain of the rights granted by [...***...] to Sublicensor in the Master License Agreement; 

NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, and in
consideration of the following mutual promises and covenants, the parties hereto agree as follows: 
  

	1.	 DEFINITIONS 

For purposes of this Agreement, the following terms shall have the meaning as set forth below: 

 

	 	1.1.	 “Affiliates” means a person or entity that directly or indirectly through one or more
intermediaries, controls, or is controlled by, Sublicensee. As used in this definition, the term “control,” including the correlative terms “controlling,” and “controlled by” means the possession, directly or
indirectly, of the power to direct or cause the direction of management or policies (whether through ownership of securities or any partnership or other ownership interest, by contractor otherwise) of a person or entity. 

 

	 	1.2.	 “Agreement Year” shall be a twelve (12) calendar month period beginning July 1 and ending
June 30 of the following year, except that the first Agreement Year shall begin on the Effective Date and shall end June 30, 2014. 

  

	 	1.3.	 “Licensed Patent” means US Patent No. [...***...], and any reexaminations and reissues
thereof. 

  

	 	1.4.	 “Patent Rights” means only [...***...] of the Licensed Patent. 

 

	 	1.5.	 “Licensed Field” shall be limited to the field of nucleic acid analysis. 

 

	 	1.6.	 “Licensed Territory” shall be limited to the United States. 

 

	 	1.7.	 

  

	 	1.8.	 “Master, License Agreement” means that license agreement entered into between [...***...] and
Sublicensor on [...***...], under which Sublicensor has received a license to the Patent Rights. 

  

	 	1.9.	 “Non-Commercial Research Purposes” shall mean the use of the
inventions of the Patent Rights and/or Improvements for academic research purposes or other not-for-profit or scholarly purposes not involving the use of the inventions
of the Patent Rights or Improvements to perform services for a fee or for the production or manufacture of products for sale to third parties. 

  

	 	1.10.	 “Products” shall refer to and mean any and all products sold for use in the Licensed Territory that
employ or are in any way produced by the practice of an invention claimed in a 

  
 ***Confidential
Treatment Requested 
 1 lndustry3200 -BioNano Genomics Sublicense 

 
Valid Claim of the Patent Rights or that would otherwise constitute infringement of any Valid Claim of the Patent Rights. 
  

	 	1.11.	 “Selling Price” shall mean, in the case of Products and Services that are sold or leased, the
[...***...] of Products and Services [...***...]. The “Selling Price” for a Product that is transferred or Service is provided to a third party for promotional purposes without charge or at a discount shall be [...***...]
of that type of Product or Service [...***...]. 

  

	 	1.12.	 “Services” shall refer to and mean any and all services performed in the Licensed Territory that
employ or are in any way produced by the practice of an invention claimed in a Valid Claim of the Patent Rights or that would otherwise constitute infringement of any Valid Claims of the Patent Rights. 

 

	 	1.13.	 “Third Party” means any person or entity other than [...***...], Sublicensor, Sublicensee, or
an Affiliate of either of them. 

  

	 	1.14.	 “Valid Claim” means an issued claim of the Patent Rights, where the claim (a) has not expired
or lapsed and (b) has not been held to be invalid or unenforceable by (i) a final judgment of a court of competent jurisdiction from which no appeal can be or is taken or (ii) a governmental authority having the jurisdiction to issue
or to review the validity of patent claims from which no appeal can be or is taken. 

  

	2.	 LICENSE 

  

	 	2.1.	 Nonexclusive License. Sublicensor grants to Sublicensee, and Sublicensee hereby accepts, a nonexclusive
right and license to practice the Patent Rights In the Licensed Territory and in the Licensed Field, with the right to make, have made, use, have used, import, export, market, distribute, offer for sale and sell Licensed Product, and to allow its
customers to use the same. Sublicensor grants no sublicense to any other claim or patent that Sublicensor has licensed under the Master License Agreement. 

  

	 	2.2.	 Sublicensing. Sublicensee shall have no right to further sublicense the rights granted hereunder,
except with the consent of Sublicensor, which consent shall not unreasonably be withheld in the case of a sale, merger, acquisition, with the intended recipient of such sublicense. In no event shall there be multiple concurrent sublicensees.

  

	 	2.3.	 Acknowledgement of Covenant not to Sue. Sublicensor acknowledges that in a separate Option Agreement,
[...***...] has granted Sublicensee a covenant not to sue under certain other intellectual property rights in the [...***...] portfolio. Sublicensor covenants to take no action to undermine, circumvent, interfere with or frustrate the
grant of such rights by [...***...] or the maintenance of such rights by Sublicensee. 

  

	3.	 FINANCIAL TERMS 

  
 ***Confidential
Treatment Requested 
 2 lndustry3200 -BioNano Genomics Sublicense 

	 	3.1.	 Sublicense Fees: As consideration for the grant and maintenance of this Agreement, Sublicensee shall
pay, and Sublicensor shall accept, a sublicense fee as follows: 

  

	 	3.1.1.	 $[...***...] within thirty (30) days of the full execution of this Agreement or of the Master
License Agreement, whichever is later. 

  

	 	3.1.2.	 $[...***...] on July 1 of the second Agreement Year. 

 

	 	3.1.3.	 $[...***...] on July 1 of the third Agreement Year. 

 

	 	3.1.4.	 $[...***...] on July 1 of the fourth Agreement Year. 

 

	 	3.1.5.	 $[...***...] on July 1 of the fifth Agreement Year. 

 

	 	3.1.6.	 $[...***...] on July 1 of each subsequent Agreement Year, if the term of this Agreement is extended
to include such Agreement Year. 

  

	 	3.2.	 Royalties: Sublicensee agrees to pay to Sublicensor as “earned royalties” a royalty
calculated as a percentage of the Selling Price of Products and Services in accordance with the terms and conditions of this Agreement. The royalty is deemed earned as of [...***...]. The royalty shall remain fixed while this Agreement is in
effect at a rate of [...***...] of the Selling Price of Products and Services., with the proviso that a minimum royalty payment (“Minimum Annual Royalty”) for each Agreement Year shall be [...***...]. In consideration of
Sublicensee being an early licensee of the inventions of the Patent Rights, [...***...] and Sublicensor agree that [...***...] Products sold, leased or otherwise transferred by Sublicensee that are [...***...] shall
[...***...]; provided, however, Sublicensee will report the sale, lease or transfer of such [...***...] Products on its [...***...], and thereafter, [...***...]. For clarity, the foregoing does not apply to any other Product
or sublicensee of Sublicensee. 

  

	 	3.3.	 Antistacking: If Sublicensee is required to pay royalties to one or more independent third parties
during any calendar year pursuant to a license or similar right in the absence of which Sublicensee could not legally make, use or sell Products, then the royalty payable hereunder will be reduced by [...***...] for each additional
[...***...] of royalties payable for all of the additional licensing components, to Sublicensor. Notwithstanding the foregoing, in no event shall the royalty due Sublicensor be reduced by more than [...***...]. 

 

	 	3.4.	 Royalty Payments: Royalty payments shall be due [...***...] following the end of the calendar
quarter ending on March 31, June 30, September 30, or December 31, and shall be accompanied by a royalty report indicating each Licensed Product and Net Sales for such Licensed Product, including the basis for calculating the
royalty. 

  

	 	3.5.	 Late Payments: The balance of any amounts owed to Sublicensor under this Agreement which remain unpaid
more than [...***...] after they are due to Sublicensor shall accrue interest until paid at the rate of the lesser of [...***...] per month or the maximum amount allowed under applicable law. However, in no event shall this interest
provision be construed as a grant of permission for any payment delays. 

  

	 	3.6.	 Records: Sublicensee agrees to keep [...***...] records to enable the ready determination of Net
Sales and any antistacking reduction in royalty pursuant to Section 

  
 ***Confidential
Treatment Requested 
 3 lndustry3200 -BioNano Genomics Sublicense 

	 	 
3.3, and to provide such records within [...***...] of request by [...***...] or Sublicensor for inspection by a certified public accountant designated by Sublicensor or
[...***...], in the United States during Sublicensee’s regular business hours and at [...***...]’s or Sublicensor’s expense, but no more often than once per Agreement Year. If Sublicensee has claimed an antistacking
reduction in royalty pursuant to Section 3.3, certain underlying documentation will be revealed to the certified public accountant in confidence, but the certified public accountant shall not disclose the details revealed in such underlying
documentation to Sublicensor, but only conclusions drawn therefrom. In the event an examination of Sublicensee’s records reveals an underpayment of the lesser of [...***...] or [...***...] of the accurate amounts due hereunder,
Sublicensee shall pay all reasonable charges of the certified public accountant for the examination of records, in addition to paying the balance due within [...***...], plus interest thereon as set forth above. Sublicensee agrees to maintain
the records required hereunder for [...***...] after the last royalty period to which the records refer. 

  

	 	3.7.	 Currency: All payments to be made under this Agreement shall be made in U.S. dollars.

  

	4.	 TERM & TERMINATION 

 

	 	4.1.	 Unless otherwise terminated under any other provision of this Agreement, this Agreement shall expire on the
earlier of the end of the fifth (5th) Agreement Year or upon the termination of the Master License Agreement. 

 

	 	4.2.	 So long as the Master License Agreement is not terminated, Sublicensee may extend the termination date under
Section 4.1 in one year increments by making payment of the Sublicense Fee in Section 3.1.6 on or before July 1 of each subsequent Agreement Year, but in no event shall the termination date extend beyond the expiration or lapse of the
Patent Rights. 

  

	 	4.3.	 Sublicensee may terminate this Agreement at any time after the end of the fifth Agreement Year, with or
without cause, by providing ninety (90) days prior written notice to Sublicensor. 

  

	 	4.4.	 Either party may terminate this Agreement in the event of: (i) an uncured material breach by the other
party of a specified obligation or warranty under the Agreement and only upon sixty (60) days notice; or (ii) the other party is adjudged bankrupt, or subject to appointment of a receiver or trustee in bankruptcy, becomes insolvent, or
makes an assignment for the benefit of creditors. 

  

	 	4.5.	 If a party (the “breaching party”) at any time fails to observe or perform any of the material terms
of this Agreement, including but not limited to, the obligations to make any payment or royalty, the other party may make written demand that the breaching party remedy any such failure. If the breaching party does not remedy any such failure within
ninety (90) days following the other party’s demand, the other party by written notice may, at its option, terminate this Agreement. Upon timely remedy of a breach by either party, the Agreement shall remain in full force and effect. If a
party believes it has fully cured a noticed breach, but the extent of cure is subject to a bona fide dispute by the other non-breaching party, then the dispute shall be subjected to dispute resolution
hereunder. 

  

	 	4.6.	 Upon termination or expiration of the Agreement, duties and obligations incurred under the Agreement prior to
termination shall survive termination. Obligations of royalty payments, as well as causes of action or claims arising out of a breach or default under this Agreement, shall all survive termination. Sublicensee shall make a final accounting and
royalty payment to Sublicensor within thirty (30) days of the termination or expiration of this Agreement. 

  

	5.	 MUTUAL INDEMNIFICATION 

  
 ***Confidential
Treatment Requested 
 4 lndustry3200 -BioNano Genomics Sublicense 

	 	5.1.	 Sublicensee’s Right to Indemnification. Sublicensor shall indemnify, defend, and hold harmless
Sublicensee and its Affiliates, and their respective employees, officers, independent contractors, consultants, or agents, and their respective successors, heirs and assigns and representatives (the “Sublicensee lndemnitees”), from and
against any and all Third Party claims, threatened claims, damages, losses, suits, proceedings, liabilities, costs (including reasonable legal expenses, costs of litigation, and reasonable attorney’s fees) or judgments, whether for money or
equitable relief, of any kind (Losses and Claims), to the extent arising out of or relating to, directly or indirectly: (a) the negligence, recklessness, or wrongful intentional acts or omissions of Sublicensor, its Affiliates and its or their
respective employees, officers, independent contractors, consultants, or agents, in connection with Sublicensor’s performance of its obligations or exercise of its rights under this Agreement; and (b) any breach by Sublicensor of any
representation, warranty, covenant, or obligation set forth in this Agreement; except in any such case for Losses and Claims to the extent reasonably attributable to any recklessness, willful misconduct, or breach of this Agreement by Sublicensee or
a Sublicensee lndemnitee, or (c) resulting from Sublicensor’s production, manufacture, sale, use, lease, consumption or advertisement of Products and Services arising from any right or obligation of Sublicensor under the Master License
Agreement. 

  

	 	5.2.	 Sublicensor’s Right to Indemnification. Sublicensee shall indemnify, defend, and hold harmless
Sublicensor and its Affiliates, and their respective employees, officers, and their respective successors, heirs and assigns and representatives (the “Sublicensor lndemnitees”), from and against any and all Third Party claims, threatened
claims, damages, losses, suits, proceedings, liabilities, costs (including reasonable legal expenses, costs of litigation, and reasonable attorney’s fees) or judgments, whether for money or equitable relief, of any kind (Losses and Claims), to
the extent arising out of or relating to, directly or indirectly: (a) the negligence, recklessness, or wrongful intentional acts or omissions of Sublicensee, its Affiliates and its or their respective employees, officers, independent
contractors, consultants, or agents, in connection with Sublicensee’s performance of its obligations or exercise of its rights under this Agreement; and (b) any breach by Sublicensee of any representation, warranty, covenant, or obligation
set forth in this Agreement; except in any such case for Losses and Claims to the extent reasonably attributable to any recklessness, willful misconduct, or breach of this Agreement by Sublicensor or a Sublicensor lndemnitee; or (c) resulting
from Sublicensee’s production, manufacture, sale, use, lease, consumption or advertisement of Products and Services arising from any right or obligation of Sublicensee hereunder. 

 

	 	5.3.	 Process for Indemnification. A party’s obligation to defend, indemnify and hold harmless the other
party under this Section 5 (Mutual Indemnification) shall be conditioned upon the following: 

  

	 	(a)	 A party seeking indemnification under this Section 5 (the “lndemnitee”) shall give prompt
written notice of the claim to the other party (the “lndemnitor”). 

  

	 	(b)	 Each party shall promptly to the other party copies of all papers and official documents received in respect
of any Losses and Claims. The lndemnitee shall cooperate as requested by the lndemnitor in the defense against any Losses and Claims. 

  

	 	(c)	 The lndemnitor shall have the right to assume and control the defense of the indemnification claim at its own
expense with counsel selected by the lndemnitor and reasonably acceptable to the lndemnitee; provided, however, that an lndemnitee shall have the right to retain its own counsel, with the fees and expenses to be paid by the lndemnitee, if
representation of such lndemnitee by the counsel retained by the lndemnitor would be inappropriate due to actual or potential differing interests between such lndemnitee and any other party represented by such counsel in such proceedings. If the
lndemnitor does not assume the defense of the indemnification claim as described in this Section 5.3(c), the lndemnitee may defend the indemnification claim but shall have no obligation to do so. The lndemnitee shall not settle or compromise
the indemnification claim without the prior written consent of the lndemnitor, and the lndemnitor shall not 

  
 5 lndustry3200 -BioNano
Genomics Sublicense 

	 	 
settle or compromise the indemnification claim in any manner which would have an adverse effect on the lndemnitee’s interests (including any rights under this Agreement or the scope or
enforceability of the Patent Rights or Confidential Information or other rights licensed to Sublicensee by Sublicensor hereunder), without the prior written consent of the lndemnitee, which consent, in each case, shall not be unreasonably withheld,
delayed, or conditioned. The lndemnitee shall reasonably cooperate with the lndemnitor at the lndemnitor’s expense and shall make available to the lndemnitor all pertinent information under the control of the lndemnitee. The lndemnitor shall
not be liable for any settlement or other disposition of Losses and Claims by the lndemnitee which is reached without the written consent of the lndemnitor, which consent shall not be unreasonably withheld, conditioned, or delayed.

  

	6.	 Insurance. 

Licensee warrants that it now maintains and will continue to maintain liability insurance coverage appropriate to the risk
involved in marketing the Products and Services subject to this Agreement and that such insurance coverage lists Sublicensor, [...***...] and the inventors of the Patent rights as additional insureds. Upon Sublicensor’s request, Licensee
will present evidence to Sublicensor that such coverage is being maintained. 
  

	7.	 TRANSFER OF RIGHTS 

Sublicensee shall have the right to transfer this Agreement to another entity that agrees to be bound by the provisions hereof,
with the prior written consent of [...***...] and prior written notification to Sublicensor. 
  

	8.	 CONFIDENTIALITY 

Confidential information of Sublicensee may be revealed to or ascertained by Sublicensor in the course of Sublicensee
performing under this Agreement, including in connection with royalty reports and associated records. “Confidential Information” shall include all information concerning a Sublicensee’s business and any other information marked
confidential or accompanied by correspondence indicating such information is confidentially exchanged between the parties hereto. Sublicensor agrees to keep confidential any information identified as confidential by Sublicensee, using methods at
least as stringent as Sublicensor uses to protect its own confidential information, and not to use any of Sublicensee’s Confidential Information to its advantage or Sublicensee’s detriment, including but not limited to using such
Confidential Information in Sublicensor’s patent prosecution. In like manner, Sublicensee and its employees shall maintain in confidence the terms of the Master License Agreement. The confidentiality and nonuse obligations set forth above apply
to all or any part of the Confidential Information disclosed hereunder except to the extent that: 

  
 ***Confidential
Treatment Requested 
 6 lndustry3200 -BioNano Genomics Sublicense 

	 	8.1.	 Sublicensor can show by written record that it possessed the information prior to its receipt from
Sublicensee; 

  

	 	8.2.	 the information was already available to the public or became so through no fault of Sublicensor;

  

	 	8.3.	 the information is subsequently publicly disclosed by Sublicensee or by a third party that has the right to
disclose it free of any obligations of confidentiality; 

  

	 	8.4.	 the information is required by law, rule, regulation or judicial process to be disclosed (if such requirement
arises, Sublicensor will, prior to any such disclosure, promptly notify Sublicensee and provide assistance in any reasonable effort to obtain confidential treatment with respect to such disclosure); or 

 

	 	8.5.	 [...***...] years have elapsed from the termination of this Agreement. 

 

	9.	 RIGHTS IN BANKRUPTCY. 

All rights and licenses granted under or pursuant to this Agreement by Sublicensor are, and shall otherwise be deemed to be,
for purposes of Section 365(n) of the United States Bankruptcy Code, licenses of right to “intellectual property” as defined under Section 91 of the United States Bankruptcy Code or any applicable foreign equivalent thereof. The
parties agree that the Sublicensee, as a licensee of such rights under this Agreement, shall retain and may fully exercise all of its rights and elections under the United States Bankruptcy Code. 

 

	10.	 RESOLUTION OF DISPUTES 

 

	 	10.1.	 Informal Dispute Resolution. The parties shall attempt, whenever possible, to discuss and resolve any
Disputes on an informal basis,. A party invoking these dispute resolution procedures shall deliver a notice to the other party (a “Dispute Notice”) of the claims it intends to bring and the relief sought, including sufficient details
regarding the factual, contractual or other legal bases for the party’s claim as reasonably required to enable the party receiving the Dispute Notice to evaluate the claim and respond thereto. 

Upon receipt of a Dispute Notice, the receiving party, if it so desires, shall have fifteen (15) days in which to deliver
its own Dispute Notice to the first party, responding to the first Dispute Notice and specifying additional Disputes, if any, to be resolved. After the second Dispute Notice is delivered or upon expiration of the fifteen (15) day period
therefor, whichever occurs first (the “Dispute Notification Deadline”), the parties shall promptly schedule one or more meetings to discuss and attempt in good faith to resolve all Disputes described in the Dispute Notice(s). Such meetings
shall be attended by the parties or their representatives with full authority to settle the Disputes at issue. 
  

	11.	 CONTEST OF VALIDITY 

 

	 	11.1.	 Sublicensee shall provide [...***...] at least [...***...] prior written notice before filing any
action that contests the validity of any Patent Rights during the term of this Agreement. 

	 	

	 	11.2.	 In the event that Sublicensee files any action contesting the validity of any Patent Rights, Sublicensee shall
pay a royalty rate of [...***...] specified in Section 3.2 or 3.3 of this Agreement, as applicable, for all Products and Services sold during the pendency of such action. Moreover, should the outcome of such contest determine that any
claim of the Patent Rights challenged is valid and would be infringed by a Licensed Product sold by 

  
 ***Confidential
Treatment Requested 
 7 lndustry3200 -BioNano Genomics Sublicense 

	 	 
Sublicensee, if not for the Sublicensee granted by this Agreement, Sublicensee shall thereafter, for the remaining term of this Agreement, pay a royalty rate of [...***...] specified in
Section 3.2. or 3.3 of this Agreement, as applicable. 

  

	 	11.3.	 In the event that Sublicensee contests the validity of any Patent Rights during the term of this Agreement,
Sublicensee agrees to pay to Sublicensor all royalties due under this Agreement during the period of the challenge. For the sake of clarity, such amounts shall not be paid into any escrow or other account, but directly to Sublicensor, and shall not
be refunded. 

  

	12.	 PATENT MARKING 

Sublicensee shall mark all Products and Services or packaging thereof with the appropriate patent number reference in
compliance with the requirements of 35 U.S.C. §287. 
  

	13.	 USE OF NAMES 

Sublicensee shall not use [...***...]’s or Sublicensor’s name, the name of any inventor of the Patent Rights,
or the name of the [...***...] in sales promotion, advertising, or any other form of publicity without the prior written approval of the entity or person whose name is being used. 

 

	14.	 IMPROVEMENTS 

 

	 	14.1.	 Sublicensee hereby grants to [...***...] a nonexclusive, royalty-free, irrevocable, paid-up license, with the right to grant sublicenses to non-profit research institutions and governmental agencies, to practice and use “Improvements” for Non-Commercial Research Purposes. “Improvements” shall mean any patented modification of an invention claimed in the Patent Rights, invented by Sublicensee during the term of this Agreement, that
(1) would be infringed by the practice of an invention claimed in the Patent Rights; or (2) if not for the license granted under this Agreement, would infringe one or more claims of the Patent Rights 

	 	

	 	14.2.	 In the event that Sublicensee discontinues use or commercialization of the Improvements, Sublicensee shall
grant [...***...] an option to obtain a nonexclusive, royalty-bearing license, with the right to grant sublicenses, to practice and use said Improvements for commercial purposes; except for Improvements (1) that would not necessarily be
infringed by practicing an invention claimed in the Patent Rights or (2) that are capable of substantial noninfringing use. The scope of a sublicensee’s obligation relating to Improvements shall be limited to the claims actually licensed
to that sublicensee. Licensee shall provide [...***...] with written notice that Licensee and its sublicensee(s) intend to discontinue such use or commercialization immediately upon making a decision. [...***...]’s option with
respect to each Improvement shall expire [...***...] after [...***...]’s receipt of said written notice from Licensee. The failure of [...***...] to timely exercise its option under this paragraph shall be deemed a waiver of
[...***...]’s option, but only with respect to the Improvements so disclosed. 

	 	

	15.	 REPRESENTATIONS AND WARRANTIES 

 

	 	15.1.	 The Parties’ Representations and Warranties. Each party hereby represents and warrants to the
other party, as of the Effective Date, as set forth below: 

  

	 	15.1.1.	 Such party (a) is a corporation duly organized and subsisting under the laws of its jurisdiction of
organization, and (b) has full power and authority and the legal right to own and operate its property and assets and to carry on its business as it is now being conducted and as it is contemplated to be conducted by this Agreement.

  
 ***Confidential
Treatment Requested 
 8 lndustry3200 -BioNano Genomics Sublicense 

	 	15.1.2.	 Such party has the power, authority and legal right, and is free to enter into this Agreement and, in so
doing, will not violate any other agreement to which such party is a party as of the Effective Date, or conflict with the rights granted to any Third Party. 

  

	 	15.1.3.	 This Agreement has been duly executed and delivered on behalf of such party and constitutes a legal, valid,
and binding obligation of such party and is enforceable against it in accordance with its terms, subject to the effects of bankruptcy, insolvency, or other laws of general application affecting the enforcement of creditor rights and judicial
principles affecting the availability of specific performance and general principles of equity. 

  

	 	15.1.4.	 Such party has taken all corporate action necessary to authorize the execution and delivery of this Agreement.

  

	 	15.1.5.	 The execution and delivery of this Agreement and the performance of such party’s obligations hereunder
(i) do not conflict with or violate any requirement of applicable laws or any provision of the articles of incorporation, bylaws, limited partnership agreement, or any similar instrument of such party, as applicable, in any material way, and
(ii) do not conflict with, violate, or breach or constitute a default or require any consent under, any applicable laws or any contractual obligation or court or administrative order by which such party is bound. 

 

	 	15.1.6.	 The parties acknowledge that [...***...] makes no representations, extends no warranties of any kind,
either express or implied, and assumes no responsibilities whatsoever with respect to the use, sale, or other disposition by Sublicensee or its vendees or other transferees of Products and Services incorporating or made by use of the Patent Rights.

  

	 	15.2.	 Sublicensor’s Representations, Warranties and Covenants. Sublicensor hereby represents, warrants
and covenants to Sublicensee, as set forth below: 

  

	 	15.2.1.	 It is the licensee of the Patent Rights from [...***...] and it possesses all rights necessary to grant
the sublicenses contained in this Agreement; 

  

	 	15.2.2.	 It has not previously granted, and will not grant, any right, license or interest in the Patent Rights, or any
portion thereof, inconsistent with the rights and licenses granted to Sublicensee herein; 

  

	 	15.2.3.	 It is not aware of any pending or threatened litigation, nor has it received any written communications,
alleging that that the commercialization of the Products and/or Services or of any compound or product claimed in any Patent Rights would violate any intellectual property or other rights of any Third Party or that the Patent Rights are invalid or
unenforceable; 

  

	 	15.2.4.	 as of the Effective Date, no Third Party has any interest in and to any of the Patent Rights;

  

	16.	 LIMITATION OF LIABILITY AND EXCLUSION OF DAMAGES; DISCLAIMER OF WARRANTY. 

 

	 	16.1.	 WITHOUT LIMITING THE PARTIES’ OBLIGATIONS UNDER SECTION 14 (REPRESENTATIONS AND WARRANTIES), NEITHER
PARTY SHALL BE LIABLE TO THE OTHER PARTY FOR SPECIAL, INDIRECT, INCIDENTAL, PUNITIVE, OR CONSEQUENTIAL DAMAGES (INCLUDING DAMAGES RESULTING FROM LOSS OF USE, LOSS OF PROFITS, INTERRUPTION OR LOSS OF BUSINESS, OR OTHER ECONOMIC LOSS) ARISING OUT OF
THIS AGREEMENT OR WITH RESPECT TO A PARTY’S PERFORMANCE OR NON-PERFORMANCE HEREUNDER. 

  
 ***Confidential
Treatment Requested 
 9 lndustry3200 -BioNano Genomics Sublicense 

	 	16.2.	 EXCEPT AS EXPRESSLY PROVIDED IN THIS AGREEMENT, NEITHER PARTY PROVIDES ANY REPRESENTATIONS OR WARRANTIES,
WHETHER WRITTEN OR ORAL, EXPRESS OR IMPLIED, REGARDING THE LICENSE PRODUCTS, AND EACH PARTY HEREBY DISCLAIMS ALL OTHER REPRESENTATIONS OR WARRANTIES, WHETHER WRITTEN OR ORAL, EXPRESS AND IMPLIED, INCLUDING THE IMPLIED WARRANTIES OF MERCHANTABILITY,
FITNESS FOR A PARTICULAR PURPOSE, AND FREEDOM FROM INFRINGEMENT OF THIRD PARTY RIGHTS. THE PARTIES AGREE THAT SUBLICENSEE IS UNDER NO OBLIGATION TO MAKE ANY EFFORTS TO COMMERCIALIZE OR EXPLOIT THE PATENT RIGHTS, AND SUBLICENSOR EXPLICITLY DISCLAIMS
ANY SUCH OBLIGATION. 

  

	17.	 GENERAL PROVISIONS 

 

	 	17.1.	 Governing Law. 

 

	 	17.1.1.	 This Agreement shall be governed by and interpreted in accordance with the substantive laws of the State of
California, U.S. without regard to its or any other jurisdiction’s choice of law rules that would result in the application of the laws of any state other than the State of California, U.S. All questions concerning the construction or effect of
patent applications and patents shall be decided in accordance with the laws of the country in which the particular patent application or patent concerned has been filed or granted, as the case may be. 

 

	 	17.1.2.	 Sublicensor and Sublicensee hereby submit to the exclusive jurisdiction of the state and federal courts
located in San Diego, California, U.S. for any action or proceeding arising out of or relating to this Agreement, and Sublicensor and Sublicensee hereby agree that all claims in respect of such action or proceeding may be heard and determined
exclusively in any such state or federal court, and the parties hereby irrevocably submit to the exclusive jurisdiction of such courts in any such action or proceeding and irrevocably waive the defense of an inconvenient forum to the maintenance of
any such action or proceeding. A final judgment in any action or proceeding shall be conclusive and may be enforced in other jurisdictions by suit on the judgment or in any other manner provided by law. 

 

	 	17.2.	 Legal Counsel; Cooperation in Drafting. Each party recognizes that this is a legally binding contract
and acknowledges and agrees that they have had the opportunity to consult with legal counsel of their choice concerning the legal and practical effects of this Agreement. Each party has cooperated in the drafting, negotiation and preparation of this
Agreement. Hence, in any construction to be made of this Agreement, the same shall not be construed against either party on the basis of that party being the drafter of such language. 

	 	

	 	17.3.	 Notices. All communications hereunder shall be in writing, electronic mail or by confirmed fax, and
shall be deemed to have been duly given (a) upon personal delivery, (b) upon deposit with a recognized courier with next-day delivery instructions, or (c) one (1) business day after sending, if
sent by electronic mail and no delivery failure notification has been received; to the address set forth below or such other address as either party may specify by notice sent in accordance with this Section 16.3 (“Notices”):

 If to Sublicensor, addressed to:  Industry 3200 Inc. 

Attn: [...***...] 

1155 Camino Del Mar #118 

Del Mar, CA 92014 

Email: [...***...] 

  
 ***Confidential
Treatment Requested 
 10 lndustry3200 -BioNano Genomics Sublicense 

 With a copy to: 

CapialP 

Attn: [...***...] 

11011 Torreyana Road 

San Diego, CA 92121 

Email: [...***...] 

If to Sublicensee, addressed to: 

BioNano Genomics, Inc. 

Attention: President 

9640 Towne Centre Drive, Suite 100 

San Diego, CA 92121 

With a copy to: 

Knobbe Martens Olson & Bear 

Attention: [...***...] 

12790 El Camino Real 

San Diego, CA 92130 

11.3. Entire Agreement. This Agreement constitutes the entire agreement among the parties hereto with respect to the
subject matter hereof and supersedes all prior agreements and understandings relative thereto. The provisions of this Agreement shall be modified only by an agreement in writing signed by both parties hereto. 

11.4. No Waiver. The failure of any party to enforce any of the provisions of this Agreement shall not be construed to
be a waiver of the right of such party thereafter to enforce such provisions. 
 11.5. Binding on Successors. This
Agreement shall be binding upon the parties, their affiliates, agents, successors and assigns. 
 11.6. Severability.
In the event any provision of this Agreement is invalid or unenforceable or is prohibited by law, the remaining provisions of this Agreement shall remain in full force and effect, and the remainder of this Agreement shall be valid and binding as
though such invalid, unenforceable, or prohibited provision were not included herein. 
 11.7. Attorneys’ Fees.
If any legal action or any arbitration or other proceeding is brought for the enforcement of this Agreement, or because of an alleged dispute, breach, default, or misrepresentation in connection with any of the provisions of this Agreement, the
successful and/or prevailing party or parties shall be entitled to recover reasonable attorneys’ fees and other costs incurred in that action or proceeding, including expert witness fees, in addition to any other relief to which it or they may
be entitled. 
 11.8. Equitable Relief. The parties acknowledge that any breach or violation of the confidentiality
terms of this Agreement will result in immediate and irreparable damage to the non-breaching party and that there would be no adequate remedy at law for either party’s failure to comply with the terms of this Agreement. Each party acknowledges
that the other is entitled to equitable relief, including a preliminary and/or permanent injunction and such other relief as a court with jurisdiction may deem proper, to prohibit any further or continuing breach or failure to comply with the
confidentiality terms of this Agreement. 

  
 ***Confidential
Treatment Requested 
 11 lndustry3200 -BioNano Genomics Sublicense 

 11.9. Headings. The paragraph headings herein are for convenience only and
shall not be interpreted to limit or affect in any way the meaning of the language contained herein. 
 11.10.
Confidentiality. This Agreement and the terms thereof shall be treated as confidential information of the parties, and, without the consent of the other two parties, shall not be disclosed to entities that are not party to this Agreement and
are not evaluating a party for potential investment or acquisition. A party may disclose the terms of this Agreement, without consent, to entities evaluating a party for potential investment or acquisition, provided that such entities agree to keep
the terms of this Agreement confidential. 
 IN WITNESS WHEREOF, the parties hereto, being authorized to sign on behalf of
the entity for which they are signing and with full authority to bind such entity by that signature, have caused this Agreement to be executed as of the date first set forth above. Each copy hereof for all purposes shall be deemed an original. 

 

									
	SUBLICENSOR	 		 	SUBLICENSEE
					
	By:	 	/s/ Leslie A. Hickle	 		 	By:	 	/s/ R. Erik Holmlin

									
					
	Printed Name:	 	Leslie A. Hickle	 		 	Printed Name:	 	R. Erik Holmlin

									
			
	Title: Co-Founder & CBO	 		 	Title: CEO
					
	Dated:	 	Jan 7, 2014	 		 	Dated:	 	9-Jan-2014

  
 12 lndustry3200 -BioNano
Genomics Sublicense

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00285-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00285-of-00352.parquet"}]]